TGFβR2 extracellular domain cleaved molecule, fusion protein of TGFβR2 extracellular domain cleaved molecule and anti-EGFR antibody, and antitumor uses of the fusion protein
A truncated TGFβR2 extracellular domain fusion protein addresses the limitations of separate TGF-β and EGFR treatments by concurrently targeting both pathways, effectively inhibiting tumor growth and overcoming resistance.
Patent Information
- Application Number
- KR1020227041598
- Authority / Receiving Office
- KR · KR
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-04-28
- Filing Date
- 2021-04-26
- Publication Date
- 2026-11-06
- Estimated Expiration
- 2041-04-26
AI Technical Summary
Current treatments targeting TGF-β and EGFR pathways separately are insufficient for effectively inhibiting tumor progression and resistance to EGFR-targeted therapies, as TGF-β signaling synergizes with EGFR to promote tumor growth and resistance.
A novel fusion protein comprising a truncated TGFβR2 extracellular domain molecule, specifically targeting both EGFR and TGF-β pathways, is developed to treat solid tumors, including gastric cancer.
The fusion protein effectively inhibits tumor growth and overcomes resistance to EGFR-targeted therapies by simultaneously targeting both pathways, enhancing therapeutic efficacy.
Smart Images

Figure 112022126701500-PCT00128_ABST
Abstract
Description
Technology Field
[0001] Cross-reference regarding related applications
[0002] This application claims the benefit of Chinese patent application 202010351280.6 filed on April 28, 2020, the contents of which are incorporated herein by reference.
[0003] field
[0004] The present invention relates to the field of tumor immunotherapies. Specifically, the present invention relates to a cleaved TGFβR2 (immunomodulatory factor) extracellular domain molecule and a fusion protein comprising the cleaved TGFβR2 extracellular domain molecule and a targeting portion. The present invention includes pharmaceutical compositions and the use thereof as antitumor drugs. Background Technology
[0005] Transforming growth factor-β (TGF-β) belongs to the TGF-β superfamily, which regulates cell growth and differentiation. It is a pleiotropic and multifunctional cytokine that regulates cell proliferation, differentiation, and apoptosis via cell surface receptor signaling pathways in either an autocrine or paracrine manner, playing a crucial regulatory role in extracellular matrix synthesis, trauma repair, and immune function. Three isoforms—TGF-β1, TGF-β2, and TGF-β3—exist in mammals, with TGF-β1 being the most abundant and expressed isoform. TGF-β binds to TGFβR1 and TGFβR2 serine-threonine kinase receptors on the cell membrane surface, initiating classical Smad and non-Smad pathways for downstream signaling. [ 1 ]In normal in vivo homeostasis, TGF-β signaling regulates major processes such as the growth, regeneration, and differentiation of various tissues. In the immune system, TGF-β induces tolerance and suppresses inflammation. Genetic mutations can alter TGF-β signaling in tumor-initiating cells. In the early stages of tumorigenesis, TGF-β plays a crucial role in tumor suppression by inhibiting cell proliferation and inducing an apoptotic program. However, as the tumor progresses, selective pressure causes the tumor-suppressive function of TGF-β to be lost by tumor cells through other mechanisms. Acquired inactivation mutations in the TGF-β signaling pathway enable various malignant cells to grow in TGF-β-rich environments. Furthermore, tumor cells somehow convert TGF-β's pro-apoptotic ability into pro-tumor developmental functions, such as invasion and migration capabilities, and the promotion of mesenchymal transition. [ 2-4 ] TGF-β regulates various immune cell types and functions. TGF-β controls adaptive immunity by directly promoting the proliferation of Treg cells and inhibiting the production and function of effector T cells and antigen-presenting dendritic cells. TGF-β also inhibits NK cell function and converts macrophages and neutrophils into pro-tumor growth subtypes, thereby promoting the formation of the tumor microenvironment through negative tumor immune modulation. [ 4 ]TGF-β1 is often expressed at higher levels in various solid tumors, including EGFR-positive colorectal cancer, non-small cell lung cancer, and head and neck squamous cell carcinoma, than in normal paraneoplastic tissue. Clinical data suggest that TGF-β antibodies are not yet available because blocking the TGF-β pathway alone is not sufficient to fully restore the immune system that suppresses tumorigenesis.
[0006] The epidermal growth factor receptor (EGFR) is a receptor for cell proliferation and the signaling of epidermal growth factor (EGF), a member of the epidermal growth factor receptor (HER) family, a tyrosine kinase receptor with a molecular weight of 170 kDa, and a proto-oncogene C-ErbB1 It is a product of expression. [ 5 ] EGFR is divided into an extracellular ligand binding domain, a transmembrane domain, and an intracellular kinase domain. The extracellular domain of EGFR converts from a monomer to a dimer after binding to a ligand, activates the intracellular kinase domain and various downstream signaling pathways, and plays an important role in cell growth, proliferation, and differentiation. [ 6 ] High expression of EGFR enhances downstream signaling, and increased expression of mutant EGFR receptors or ligands leads to sustained activation of EGFR, while increased activity of the secretory loop and disruption of receptor downregulation mechanisms, in turn, activate genes related to tumor proliferation and differentiation, playing an important role in tumor formation and development. [ 7 ]EGFR overexpression is associated with reduced survival rates in several types of cancer, including head and neck cancer, bladder cancer, ovarian cancer, cervical cancer, and esophageal cancer. Additionally, anti-EGFR drugs have been shown to be effective in treating several types of solid tumors, such as colorectal cancer, head and neck cancer, non-small cell lung cancer (NSCLC), and pancreatic cancer, including overall survival, progression-free survival, and overall response rates. [ 8 ] Therefore, as a clear target associated with tumor proliferation, EGFR-targeted agents have become a first-line treatment option for various malignant tumors.
[0007] Although the signals initiated by TGF-β differ from those initiated by the EGF / EGFR pathway, the signaling pathways between the two can interact. TGF-β and EGFR signaling have been found to interact in various tumors and jointly promote tumor progression. TGF-β can induce EGFR trans-activation in a highly cell type and context-specific manner. For example, TGF-β promotes the migration and invasion of breast cancer cells (MDA-MB-231, T47D, 4T1) by upregulating EGFR through the classical Smad and ERK / Sp1 signaling pathways. [ 9,10] In squamous cell carcinoma (A431, SCC13), TGF-β activates the EGFR pathway through an H2O2-dependent mechanism that increases Erk1 / 2 phosphorylation levels. [ 11 ] EGF and its related downstream signaling pathways can also regulate TGF-β signaling in other cell types. For example, in human primary ovarian cancer cells, EGF induces the TGF-β-induced cell cycle regulator p15 INK4B By reducing the mRNA expression of, the sensitivity of ovarian cancer cells to the antiproliferative effect of TGF-β is reduced. [ 12 ] Oncogenic Ras in breast and lung epithelial cells reduces the cell growth inhibitory effect of TGF-β by inhibiting TGF-β-mediated signaling through the negative regulation of Smad2 and Smad3. [ 13,14 ] EGF also positively regulates Smad2 signaling in COS7 cells by increasing Smad2 phosphorylation through the ERK pathway. [ 15 ]
[0008] TGF-β and EGF synergistically promote the malignant phenotype of tumors, and studies on other tissues have shown that EGF combined with TGF-β enhances epithelial-to-mesenchymal transition (EMT). For example, EGF and TGF-β1 promote the expression of Laminin-332, thereby synergistically promoting EMT in oral epithelial carcinoma. [ 16 ] EGF and TGF-β1 promote EMT in intestinal epithelial cells by downregulating E-cadherin through the MAPK pathway rather than the PI3K, p38MAPK, JNK, or AP-1 pathways. [ 17 ] EGF and TGF-β1 induce Slug and Snail expression through Smad and MEK1 / 2-dependent signaling pathways, downregulate E-cadherin, and promote EMT in ovarian epithelial cells. [ 18 ] EGF and TGF-β1 activate the ERK1 / 2 signaling pathway, synergistically upregulate Snail protein expression, and promote EMT and migration in human renal cortical proximal tubule epithelial cells (HK-2). [ 19 ]EGF enhances TGF-β-induced EMT in lung cancer (H322, H358) and pancreatic cancer (HPAF-II, CAPAN-2) cells by promoting the binding of SHP2 and GAB1. [ 20 ]
[0009] Several clinical studies have shown that elevated TGF-β levels are closely associated with drug resistance and poor prognosis. In osteosarcoma cancer stem-like cells, TGF-β1-induced EMT reduces miR-499a expression, causing TGFβ-induced EMT-related kinases to switch to an AKT-activated EGFR-independent state, while SHKBP1 expression increases; consequently, EGFR activity decreases, and osteosarcoma resistance to EGFR kinase inhibitors is induced (Fig. 5). [ 21 ] Treg cells are one of the major cells that produce TGF-β. In tumors of patients with head and neck squamous cell carcinoma treated with cetuximab, an increase in the number of Treg cells is accompanied by an increase in TGF-β levels; however, TGF-β levels are even high in patients with poor cetuximab efficacy. [ 22 ] Elevated TGF-β can induce resistance to EGFR antibody therapy by inhibiting the expression of molecular effectors involved in effector cell-mediated cytotoxicity, activating the EGFR-independent AKT pathway, and enhancing EMT induction.
[23] In EGFR-mutated non-small cell lung cancer, the classic TGF-β / Smad signaling pathway is implicated in the development of PD-L1-induced tumor resistance to EGFR kinase inhibitors. [ 24 ] In breast cancer tissue, TGF-β expression was positively correlated with EGFR expression, and elevated levels of TGF-β and EGFR were associated with a poor prognosis in breast cancer patients. [ 9 ] In summary, EGFR and TGF-β play relatively independent and closely related roles in the process of tumor development. Furthermore, TGF-β is a key molecule in the development of acquired resistance in tumors to EGFR-targeted therapies. Animal studies have shown that inhibition of TGF-β enhances the in vivo antitumor effect of cetuximab on head and neck squamous cell tumor xenografts. [ 23 ] This provides a theoretical basis for combining targeted TGF-β to enhance the therapeutic efficacy of EGFR antibodies against EGFR-positive tumors.
[0010] The present invention provides a novel fusion protein comprising a truncated TGFβR2 capable of specifically targeting both EGFR and TGF-β, two relatively independent and closely related signaling pathways. This is used to treat solid tumors, including but not limited to gastric cancer.
[0011] In one aspect, the present invention provides a truncated TGFβR2 extracellular domain molecule, said molecule, compared to its natural form,
[0012] a) at least the amino acid residues at positions 6-16 are deleted, and additionally optionally, the amino acid residues at positions 17-17+n are deleted—wherein n is an integer from 1 to 10; preferably n is 2, 4, 8, 9 or 10; most preferably n is 9—; or
[0013] b) based on the deletion of amino acid residues at positions 6-26, amino acid residues at positions 5, 4-5, 3-5, 2-5, 1, 1-2, 1-3, or 1-4 are additionally deleted; or
[0014] c) Amino acid residues at positions 7-26 are deleted.
[0015] In one embodiment, the amino acid sequence includes any of sequence numbers: 48-62.
[0016] In another aspect, the present invention provides a fusion protein comprising the molecules described herein.
[0017] In one embodiment, the fusion protein comprises the following:
[0018] a) the above-mentioned cleaved TGFβR2 extracellular domain molecule, and
[0019] b) Targeting part.
[0020] In one embodiment, the fusion protein targeting portion is a cancer cell-specific targeting portion selected from an antibody or its antigen-binding fragment, its functional ligand or Fc fusion protein, and its receptor protein or Fc fusion protein.
[0021] In one embodiment, the fusion protein targeting portion is an anti-EGFR antibody or an antigen-binding fragment thereof.
[0022] In one embodiment, the N-terminus of the TGFβR2 extracellular domain molecule cleaved from the fusion protein is selectively connected to the C-terminus of the heavy chain of the targeting portion via a linker.
[0023] In one embodiment, the linker is preferably a G4S flexible peptide linker, preferably a (G4S)4 peptide linker.
[0024] In a further aspect, the present invention provides an isolated binding antibody to EGFR or an antigen-binding fragment thereof, said antibody or the antigen-binding fragment thereof, said antibody or the antigen-binding fragment thereof,
[0025] (a) A heavy chain variable region comprising heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3 domains, each comprising SEQ Nos. 19, 20, and 21, and / or
[0026] (b) includes light chain variable regions including light chain CDR1, light chain CDR2, and light chain CDR3 domains, each including sequence numbers: 16, 17, and 18.
[0027] In one embodiment, the antibody or its antigen-binding fragment comprises the following:
[0028] (a) a heavy chain variable region comprising a sequence comprising sequence number: 28, or a sequence having at least 85%, 88%, 90%, 95%, 98%, or 99% sequence identity with respect to it; and / or
[0029] (b) A light chain variable region comprising a sequence including sequence number: 29, or a sequence having at least 85%, 88%, 90%, 95%, 98%, or 99% sequence identity with respect to it.
[0030] In one embodiment, the antibody further comprises the following:
[0031] (a) a heavy chain invariant region comprising a sequence including sequence number: 30, or a sequence having at least 85%, 88%, 90%, 95%, 98%, or 99% sequence identity with respect to it; and / or
[0032] b) A light chain invariant region comprising a sequence including sequence number: 31, or a sequence having at least 85%, 88%, 90%, 95%, 98%, or 99% sequence identity with respect to it.
[0033] In one embodiment, the targeting portion of the fusion protein is selected from the anti-EGFR antibody, trastuzumab, bevacizumab, ramucirumab, ipilimumab, or panitumumab.
[0034] In one embodiment, the fusion protein comprises the following:
[0035] a) an amino acid sequence of a heavy chain comprising sequence number: 141 or a sequence having at least 85%, 88%, 90%, 95%, 98%, or 99% sequence identity with respect to this; and
[0036] b) Amino acid sequence of a light chain comprising sequence number: 23 or a sequence having at least 85%, 88%, 90%, 95%, 98%, or 99% sequence identity with respect to this,
[0037] At this time, the fusion protein comprises two heavy chains and two light chains; a disulfide bond is formed between the first light chain and the first heavy chain, a disulfide bond is formed between the second light chain and the second heavy chain, and a disulfide bond is formed between the first heavy chain and the second heavy chain.
[0038] In one embodiment, the fusion protein has a KD value of 2.92 pM to 26.3 pM, preferably 7 pM to 9 pM, and most preferably 8.77 pM for binding affinity to human EGFR protein;
[0039] It has a KD value of 23 pM to 288.3 pM, preferably 64 pM to 144 pM, and most preferably 96.1 pM for binding affinity to human TGF-β1 protein.
[0040] In a further aspect, the present invention provides a conjugate comprising the cleaved TGFβR2 extracellular domain molecule described herein, the fusion protein described herein, the antibody or antigen-binding fragment thereof described herein, and an additional therapeutic agent, wherein, preferably, said antibody or antigen-binding fragment thereof and the additional therapeutic agent are connected via a linker.
[0041] In a further aspect, the present invention provides a nucleic acid encoding the cleaved TGFβR2 extracellular domain molecule described herein, the fusion protein described herein, the antibody described herein, or the antigen-binding fragment thereof, wherein the nucleic acid is mRNA and / or DNA.
[0042] In one embodiment, the nucleic acid comprises the following:
[0043] Sequence number: any one of 32-39;
[0044] Sequence number: any one of 67-84; or
[0045] Sequence numbers 148-163, or a functional variant thereof.
[0046] In a further aspect, the present invention provides an expression vector comprising the nucleic acid described herein.
[0047] In a further aspect, the present invention provides a host cell comprising the nucleic acid described herein or the expression vector described herein.
[0048] In a further aspect, the present invention provides a method for producing the cleaved TGFβR2 extracellular domain molecule described herein, the fusion protein described herein, the antibody described herein, or an antigen-binding fragment thereof, comprising the steps of culturing a host cell described herein under conditions suitable for the expression of the protein molecule, and recovering the expressed product from a culture medium.
[0049] In a further aspect, the present invention provides a pharmaceutical composition comprising the following:
[0050] a) the cleaved TGFβR2 extracellular domain molecule described herein, the fusion protein described herein, the antibody or antigen-binding fragment thereof described herein, the conjugate described herein, the nucleic acid described herein, or the expression vector described herein; and
[0051] b) a pharmaceutically acceptable carrier; and optionally
[0052] c) One or more other therapeutic agents.
[0053] In a further aspect, the present invention provides the use of the truncated TGFβR2 extracellular domain molecule described herein, the fusion protein described herein, the antibody or antigen-binding fragment thereof described herein, the conjugate described herein, the nucleic acid described herein, the expression vector described herein, or the pharmaceutical composition described herein for the prevention and treatment of cancer, preferably for the treatment of gastric cancer.
[0054] In a further aspect, the present invention provides the use of the cleaved TGFβR2 extracellular domain molecule described herein, the fusion protein described herein, the antibody or antigen-binding fragment thereof described herein, the conjugate described herein, the nucleic acid described herein, the expression vector described herein, or the pharmaceutical composition described herein for the manufacture of a drug for the prevention and treatment of cancer, preferably for the treatment of gastric cancer.
[0055] In a further aspect, the present invention provides a pharmaceutical combination composition comprising the cleaved TGFβR2 extracellular domain molecule described herein, the fusion protein described herein, the antibody or antigen-binding fragment thereof described herein, the conjugate described herein, the nucleic acid described herein, the expression vector described herein, or the pharmaceutical composition described herein, and one or more additional therapeutic agents.
[0056] In a further aspect, the present invention provides a kit comprising the cleaved TGFβR2 extracellular domain molecule described herein, the fusion protein described herein, the antibody or antigen-binding fragment thereof described herein, the conjugate described herein, the nucleic acid described herein, the expression vector described herein, or the pharmaceutical composition described herein; preferably further comprising a device for administering a drug.
[0057] In a further aspect, the present invention provides a method for preventing and treating a neoplastic disease comprising administering to a subject the truncated TGFβR2 extracellular domain molecule described herein, the fusion protein described herein, the antibody or antigen-binding fragment thereof described herein, the conjugate described herein, the nucleic acid described herein, the expression vector described herein, or the pharmaceutical composition described herein. Brief explanation of the drawing
[0058] Fig. 1: Binding assay of murine antibody EGFR-mhPA8 to recombinant human EGFR-His protein. Fig. 2: Blocking of EGF binding to EGFR by murine antibody EGFR-mhPA8. Fig. 3: Inhibition of proliferation of MDA-MB-468 cells by murine antibody EGFR-mhPA8. Fig. 4: Binding assay of humanized antibody EGFR-HPA8 to recombinant human EGFR-His protein. Fig. 5: Blocking of EGF binding to EGFR by humanized antibody EGFR-HPA8. Fig. 6: Inhibition of proliferation of MDA-MB-468 cells by humanized antibody EGFR-HPA8 under different ligand conditions. Fig. 7: Inhibition of Fadu cell proliferation by humanized antibody EGFR-HPA8 under different ligand conditions. Fig. 8: ADCC effect mediated by humanized antibody EGFR-HPA8. Fig. 9: Effect of EGFR-HPA8 on body weight of mice subcutaneously xenografted with gastric cancer cells SNU-5. Fig. 10: Effects of EGFR-HPA8 on tumor volume and TGI results in mice subcutaneously xenografted with gastric cancer cells SNU-5. Fig. 11: Effect of EGFR-HPA8 on body weight of mice subcutaneously xenografted with non-small cell lung cancer NCI-H1975 cells. Fig. 12: Effects of EGFR-HPA8 on tumor volume and TGI results in mice subcutaneously xenografted with non-small cell lung cancer NCI-H1975 cells. Fig. 13: Schematic structure of EGFR antibody / TGFβR2 fusion protein. Fig. 14: Detection of degradation of EGFR antibody / TGFβR2 fusion protein. Fig. 15: Detection of degradation tendency of EGFR antibody / TGFβR2 fusion protein. Fig. 16: Detection of binding ability of various cleavage forms of EGFR antibody / TGFβR2 fusion protein against TGF-β1 and EGFR. Fig. 17: EGFR antibody / TGFβR2 fusion protein. Detection of the ability of the TGFβR2 cleaved EGFR antibody / TGFβR2 fusion protein to neutralize TGF-β1. Fig. 18: EGFR antibody / TGFβR2 fusion protein. Detection of the ability of the TGFβR2 cleaved EGFR antibody / TGFβR2 fusion protein to neutralize TGF-β3. Fig. 19: Ability assay of fusion protein 6 binding to TGF-β1 and TGF-β3 proteins, respectively. Fig. 20: Ability assay of fusion protein 6 to block TGF-β1 protein or TGF-β3 protein from binding to TGFβR2-Fc, respectively. Fig. 21: Testing the binding and competitive ability of fusion protein 6. Fig. 22: Affinity assay of fusion protein 6 for recombinant human EGFR protein. Fig. 23: Affinity assay of fusion protein 6 for recombinant human TGF-β1 protein. Fig. 24: Neutralizing effect of TGF-β1 by fusion protein 6 in Mv-1-lu cells. Fig. 25: Neutralizing effect of TGF-β1 by fusion protein 6 verified by a reporter gene system. Fig. 26: Inhibition of proliferation of MDA-MB-468 cells by fusion protein 6. Fig. 27: Fusion protein 6-mediated effect of ADCC. Fig. 28: Effect of fusion protein 6 on body weight of mice subcutaneously xenografted with non-small cell lung cancer NCI-H1975 cells. Fig. 29: Effect of fusion protein 6 on tumor volume in mice subcutaneously xenografted with non-small cell lung cancer NCI-H1975 cells. Fig. 30: Ultrafiltration stability test of fusion protein 6. Fig. 31: Degradation assay of X / TGFβR2 fusion protein. Fig. 32: Degradation tendency test of X / TGFβR2 fusion protein. Fig. 33: Testing the binding ability of X / TGFβR2 fusion protein to TGF-β1. Fig. 34: Assay of the ability of X / TGFβR2 fusion protein to neutralize TGF-β1 and TGF-β3. Fig. 35: Assay of X / TGFβR2 fusion protein binding to the X-part target. Specific details for implementing the invention
[0059] definition
[0060] Unless otherwise noted, all technical and scientific terms used herein have the meanings generally understood by those skilled in the art to which this invention pertains. For the purposes of this invention, the following terms are additionally defined.
[0061] As used in this specification and the appended claims, the singular forms "one," "a," "another," and "said" include the plural forms of the objects concerned, unless the context otherwise clearly indicates.
[0062] The term "truncated" form of a protein molecule refers to a modified form in which one or more amino acid residues are missing compared to the natural form of the protein molecule.
[0063] The term "fusion protein" refers to a protein molecule formed by combining two or more proteins. This is typically obtained by expressing a hybrid gene that combines two or more gene sequences inserted into an expression vector in a form that conforms to an expression frame.
[0064] The term "antibody" means an immunoglobulin molecule and means any form of antibody that exhibits the desired biological activity. Antibodies include, but are not limited to, monoclonal antibodies (including full-length monoclonal antibodies), polyclonal antibodies, and multispecific antibodies (e.g., bispecific antibodies), and even antibody fragments.
[0065] The term "variable region" refers to a domain within the heavy or light chain of an antibody involved in the binding of the antibody to an antigen. The variable regions of the heavy and light chains of natural antibodies (VH and VL, respectively) generally have similar structures and can be further subdivided into highly variable regions (called complementary decision regions, CDR) in which more conserved regions (called framework regions, FR) are interspersed.
[0066] The complementarity determining region (CDR) and framework region (FR) of a given antibody can be identified using the Kabat system (Kabat et al: Sequences of Proteins of Immunological Interest, 5th edition, US Department of Health and Human Services, PHS, NIH, NIH Publication No. 91-3242, 1991).
[0067] The term "constant region" refers to these amino acid sequences within the light and heavy chains of an antibody that do not directly participate in antibody-antigen binding but exhibit various effector functions, such as antibody-dependent cytotoxicity.
[0068] "Antigen-binding fragments of antibodies" comprise a portion of an intact antibody molecule that retains at least some of the binding specificity of a parent antibody, and typically comprises at least some portion of the antigen-binding region or variable region of the parent antibody (e.g., one or more CDRs). Examples of antigen-binding fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab')2, Fd fragment, Fd' fragment, short-chain antibody molecules (e.g., scFv, di-scFv or tri-scFv, bipartite antibody, or scFab), and single-domain antibodies.
[0069] The term "conjugate" refers to a biologically active protein or peptide molecule that forms a covalent or non-covalent bond with another molecule, namely a small molecule or biomolecule.
[0070] The term "monoclonal antibody" refers to an antibody derived from a substantially homogeneous group of antibodies, that is, a group of homogeneous antibodies that are identical to one another, except for possible mutations that may be present in very small amounts (e.g., natural mutations). Thus, the term "monoclonal" indicates the nature of the antibody, namely that it is not a mixture of unrelated antibodies. Unlike polyclonal antibody preparations, which typically contain different antibodies against different determination clusters (epitopes), each monoclonal antibody in a monoclonal antibody preparation is derived against a separate determination cluster on the antigen. In addition to its specificity, monoclonal antibody preparations generally have the advantage of not being contaminated by other antibodies. The term "monoclonal" should not be interpreted as requiring any specific method for producing the antibody. The term monoclonal antibody specifically includes chimeric antibodies, humanized antibodies, and human antibodies.
[0071] The antibody "specifically binds" to a target antigen, such as a tumor-associated antigen protein (EGFR in this invention), that is, it targets tissues or cells expressing said antigen, and means that the antibody binds to said antigen with sufficient affinity so that it can be used as a therapeutic agent without exhibiting significant cross-reactivity with other proteins, or with other proteins other than homologs and variants of said antigen target (e.g., mutant forms, splice variants, or proteolytically cleaved forms).
[0072] The term "binding affinity" refers to the sum strength of non-covalent interactions between the individual binding sites of a molecule and their binding partners. Unless otherwise specified, as used herein, "binding affinity" refers to the intrinsic binding affinity reflecting the one-to-one interaction between the members of a binding pair (e.g., antibody and antigen). "KD The binding rate constant kon and the dissociation rate constant koff are generally used to describe the affinity between a molecule (e.g., antibody) and its binding partner (e.g., antigen), that is, how tightly a ligand binds to a specific protein. Binding affinity is influenced by hydrogen bonding, electrostatic interactions, and non-covalent intermolecular interactions such as hydrophobicity and van der Waals forces between the two molecules. Additionally, the binding affinity between a ligand and its target molecule may be influenced by the presence of other molecules. Affinity can be analyzed by conventional methods known in the art, including the ELISA described herein.
[0073] The term “targeting portion” refers to a portion of a fusion protein that has the function of specifically binding to a target cell. This term includes antibodies and other natural (e.g., receptors, ligands) or synthetic (e.g., DARPin) molecules that specifically bind to a target cell. As used herein, “specifically binds to a target cell” indicates that said portion preferentially binds to a target cell within the complex mixture.
[0074] "Isolated" biomolecules are biomolecules identified and isolated from cells that naturally express the molecule. Isolated biomolecules generally include biomolecules produced by at least one purification step, as well as in situ biomolecules within recombinant cells.
[0075] The term "receptor" refers to extracellular signals (i.e., the term "ligand") Specifically recognize and combineTherefore, it is a biochemical concept referring to a class of molecules that produce specific effects within a cell. The resulting effects may last only for a short period, such as altering cellular metabolism or motility. Alternatively, they may be long-lasting effects, such as upregulating or downregulating the expression of genes or genes.
[0076] "Antibody-dependent cell-mediated cytotoxicity" or "ADCC" refers to a form of cytotoxicity in which secreted Ig binds to Fcγ receptors present on specific cytotoxic cells (e.g., NK cells, neutrophils, and macrophages), causing these cytotoxic effector cells to specifically bind to antigen-bearing target cells and subsequently kill said target cells, for example, using a cytotoxic agent. To evaluate the ADCC activity of a target antibody, in vitro ADCC assays may be performed, such as the in vitro ADCC assays described in U.S. Patent No. 5,500,362 or 5,821,337, or U.S. Patent No. 6,737,056 (Presta), and the methods are described in embodiments of this application. Effector cells useful for such assays include PBMCs and NK cells.
[0077] A fusion protein comprising a cleaved TGFβR2 extracellular domain molecule of the present invention, said cleaved TGFβR2 extracellular domain molecule, and a targeting portion
[0078] Multiple sensitive sites exist between N-terminal regions 7 and 15 of the full-length TGFβR2 extracellular domain. To improve the structural stability of the fusion protein, the inventors modified the N-terminal amino acid sequence of the TGFβR2 extracellular domain by deleting a different number of amino acids. A molecule of 15 truncated TGFβR2 extracellular domains was obtained.
[0079] The inventors used a newly isolated EGFR antibody EGFR-HPA8, trastuzumab, bevacizumab, ramucirumab, ipilimumab, or panitumumab as the targeting portion of the fusion protein and a cleaved TGFβR2 protein extracellular domain molecule as the immunomodulatory portion of the fusion protein. The cleaved TGFβR2 protein extracellular domain molecule is connected to the C-terminus of the EGFR antibody heavy chain by a homologous recombination method to form a fusion protein (EGFR / TGFβR2) comprising two chains, namely the light and heavy chains of the EGFR antibody and the TGFβR2 extracellular domain, the structure of which is illustrated in FIG. 13. In the EGFR antibody / TGFβR2 fusion protein, the amino acid at the C-terminus of the EGFR antibody heavy chain is connected to the extracellular domain of TGFβR2 in a different amino acid deletion form via a (G4S)4 linker (SEQ No. 66). In addition, the lysine residue at the C-terminus of the heavy chain of the EGFR antibody is removed, reducing the risk of proteolysis.
[0080] In a preferred embodiment of the present invention, fusion protein 6 has a binding affinity K for human EGFR protein. D The value is 8.77 pM, and the coupling constant kon value is 1.68E+06 M -1 s -1 and the dissociation constant kdis is 1.47E-04 s -1 As such, it maintains a high binding affinity for human EGFR protein. In addition, fusion protein 6 containing truncated TGFβR2 has full-length TGFβR2, and K D The value is 96.1 pM, and the coupling constant kon value is 1.53E+06 M -1 s -1 and the dissociation constant kdis is 1.47E-04 s -1 It has an affinity for human TGF-β1 protein similar to that of fusion protein 1.
[0081] nucleic acid of the present invention
[0082] The present invention also relates to a molecule comprising a truncated TGFβR2 extracellular domain molecule of the present invention, a fusion protein comprising the truncated molecule and a targeting portion, or a nucleic acid encoding portions thereof. Some exemplary sequences of such nucleic acid molecules are shown in a sequential list.
[0083] The nucleic acid molecules of the present invention are not limited to the sequences disclosed herein and include mRNA, cDNA, variants thereof, and other corresponding nucleic acid forms. Variants of the present invention may be described by reference to their physical properties in hybridization. Those skilled in the art will recognize that nucleic acid hybridization techniques can be used to identify nucleic acids as well as their complements, equivalents, or congeners.
[0084] Recombinant vectors and expression
[0085] The present invention also provides a recombinant construct comprising one or more nucleotide sequence(s) of the present invention. The recombinant construct of the present invention may be used with a vector, e.g., a plasmid, phagemid, phage, or viral vector, and a nucleic acid molecule encoding the antibody of the present invention is inserted into said vector.
[0086] The truncated TGFβR2 extracellular domain molecule, the targeting portion, and the fusion protein comprising said truncated molecule and the targeting portion of the present invention can be prepared by recombinant expression of a nucleotide sequence encoding said molecule or protein in a host cell. said molecule or protein may contain more than one amino acid sequence, and to express multiple amino acid sequences through a recombinant method, said multiple amino acid sequences are expressed in said host cell by transfecting a host cell with one or more recombinant expression vectors having the encoded nucleotide sequence. Standard recombinant DNA methods are used to prepare and / or obtain a nucleic acid encoding said molecule or protein, to incorporate said nucleic acid into a recombinant expression vector, and to introduce said vector into a host cell, for example, the literature [Reference: Sambrook, Fritsch, and Maniatis (eds.), Molecular Cloning; A Laboratory Manual, Second Edition, Cold Spring Harbor, NY, (1989), Ausubel, FM et al. (eds.) Current Protocols in Molecular Biology, Greene Publishing Associates, (1989)] and the document recorded in U.S. Patent No. 4,816,397 by Boss et al.
[0087] Examples of prokaryotic host cells are bacteria, and examples of eukaryotic host cells are yeast, insects, or mammalian cells. It must be understood that the design of expression vectors, including the selection of regulatory sequences, is influenced by various factors such as the selection of the host cell, the expression level of the target protein, and whether the expression is constitutive or inducible.
[0088] The cleaved TGFβR2 extracellular domain molecule, the targeting portion, and the fusion protein of the present invention may be recovered and purified from a recombinant cell culture by widely known methods, which include, but are not limited to, ammonium sulfate or ethanol precipitation, acid extraction, protein A affinity chromatography, protein G affinity chromatography, anion or cation exchange chromatography, cellulose phosphate chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxyapatite chromatography, and lectin chromatography. High-performance liquid chromatography ("HPLC") may also be used for purification.
[0089] use
[0090] The cleaved TGFβR2 extracellular domain molecule, antibody, and fusion protein of the present invention can be used to treat cancers such as gastric cancer.
[0091] Pharmaceutical composition
[0092] One or more types of the cleaved molecule(s), fusion protein, antibody, and antigen-binding fragment, cleaved molecule-drug conjugate, fusion protein-drug conjugate, conjugate, nucleic acid, and carrier of the present invention may be prepared with at least one other chemical agent to form a pharmaceutical composition comprising the aforementioned active ingredient(s) and one or more drug-acceptable carriers, diluents, or excipients; optionally, one or more other therapeutic agents may also be included.
[0093] Reagent kit
[0094] The present invention also relates to pharmaceutical packages and kits comprising one or more containers, said containers containing the pharmaceutical composition of the present invention mentioned above. In connection with said containers, a tip of a format prescribed by a government agency having jurisdiction over the manufacture, use, or distribution of a pharmaceutical or biological agent may be provided, which reflects the approval for human administration by the agency where said product is manufactured, used, or distributed.
[0095] Manufacturing and storage
[0096] The pharmaceutical composition of the present invention may be prepared by methods known in the art, such as conventional mixing, dissolving, granulating, grinding, emulsifying, encapsulating, embedding, or freeze-drying.
[0097] After preparing a pharmaceutical composition comprising a compound of the present invention formulated in an acceptable carrier, the composition may be placed in a suitable container and labeled for treatment of an indicated condition. Such labeling may include the amount of the drug, the frequency of administration, and the method of administration.
[0098] Drug combination
[0099] A formulation comprising the antibodies of the present invention described above is also used in combination with one or more other therapeutic agents, and the resulting combination does not cause unacceptable adverse effects.
[0100] The following embodiments are used to illustrate the invention and are not intended to limit the invention.
[0101] Examples
[0102] Example 1: Screening of murine antibodies blocking the binding of EGF to EGFR using a phage antibody display library
[0103] 1.1 Mouse Immunization and Phage Antibody Library Screening
[0104] Mice were immunized with the nucleic acid plasmids pCMV3-mFlt3L (G12FE5S01-D, designed by Sinocelltech Limited, sequence number: 142) and pCMV3-mCSF2 (G12FE5S02-D, designed by Sinocelltech Limited, sequence number: 143). The specific method was as follows: Mice were immunized by intramuscular injection of 10 M cardiotoxin 2 days prior to the first immunization. 20 g of a mixture of pCMV3-mFlt3L and pCMV3-mCSF2 with a mass ratio of 1:1 per leg was injected intramuscularly, and for each immunization, 30 g of pGS6-EGFR-TT-WPRE (manufactured by Sinocelltech Limited, SEQ No.: 144) was injected intramuscularly per leg 3 days later, and 5×10 insect cells overexpressing EGFR for 4th and 5th immunization were 6 Dogs were injected intraperitoneally, with immunization cycles of 2 weeks, 2 weeks, 2 weeks, and 2 weeks. Starting from the third immunization, blood was collected via the medial canthal plexus 7 days after each immunization. Serum titers of anti-EGFR were detected in mice coated with recombinant human EGFR protein (source: Sino Biological, Inc., Cat. 10001-H08B, hereinafter the same). Serum from the fifth immunization was collected after the criterion of reaching an 8000-fold immunoserotype titer and achieving a serum titer OD > 1 was met, 5×10 6 Intraperitoneal booster injections using canine MDA-MB468 cells were administered at 20-day intervals, and after 7 days, mice were sacrificed and spleen tissues were frozen in liquid nitrogen.
[0105] Mouse spleen tissue was extracted using TriPure Isolation Reagent (Source: Roche Cat. No. 11 667 165 001) and RNA was extracted; cDNA was obtained by reverse transcription using the TriPure Isolation Reagent kit (Source: Invitrogen Cat. No. 18080-051); PCR amplification was performed to obtain nucleotide sequences encoding the light and heavy chain variable regions of the mouse antibody; the nucleotide sequences encoding the light and heavy chain variable regions of the mouse antibody were spliced into the nucleotide sequence encoding scFv by overlap extension splicing PCR; and the light and heavy chain variable regions were connected via the following linker. [ 25 ] :
[0106] TCTAGTGGTGGCGGTGGTTCGGGCGGTGGTGGAGGTGGTAGTTCTAGATCTTCC (SEQ ID NO: 2),
[0107] Subsequently, a phage display scFv antibody library for immunized mice was constructed by linking the phage vector pComb3x (source: Sino Biological, Inc.) to the restriction endonuclease Sfi I (source: Fermentas) and electrotransforming X-Blue competent cells. Recombinant human EGFR protein was coated onto ELISA plates, and a phage library rich in anti-EGFR positive antibodies was obtained by the phage antibody panning process. Subsequently, the above library was mixed with MDA-MB-468 cells (Source: Cell Resource Center, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences), and a phage library rich in antibodies positive for MDA-MB-468 cells was screened from the library according to the phage antibody panning process (Reference: O'Brien, PM, & Aitken, R. (Eds.), Springer Science & Business Media. 2002; ISBN: 9780896037113). Phage colonies were selected from the enriched library, expressed, and their binding to recombinant human EGFR protein was detected by ELISA. A highly binding antibody clone, EGFR-mhPA8 scFv, which specifically binds to recombinant human EGFR, was screened and sent to a sequencing company for sequencing to obtain the nucleotide sequence of the EGFR-mhPA8 scFv antibody (Sequence No.: 3).
[0108] 1.2 Functional assay of murine antibodies targeting EGFR
[0109] 1.2.1 Murine Antibody Binding and Ligand Competition Functions
[0110] ELISA was used to detect the binding ability of murine antibodies to recombinant human EGFR protein. Recombinant human EGFR-His protein (source: Sino Biological, Inc., hereinafter the same) at various concentrations (1.37 ng / mL, 4.12 ng / mL, 12.35 ng / mL, 37.04 ng / mL, 111.11 ng / mL, 333.33 ng / mL, 1000 ng / mL, and 3000 ng / mL) was coated at 100 μL per well in 96-well plates and incubated overnight at 4°C. The next day, the plates were washed and blocked at room temperature for 1 hour. EGFR-mhPA8 and negative control antibody H7N9-R1 (Supplier: Sinocelltech Limited, hereinafter the same) were added at 13.89 nM and incubated for 1 hour, after which the plate was washed to remove unbound antibodies. The secondary antibody goat anti-hIgG F(ab)2 / HRP (Supplier: Jackson ImmunoResearch, Cat. 109-036-006, hereinafter the same) was added and incubated for 1 hour, after which the plate was repeatedly washed, a substrate chromogenic solution was added to induce color development, and after completion, the OD was measured using a microplate reader. 450 Reads the recombinant human EGFR-His protein concentration as the horizontal coordinate, and OD 450 Fit the S-curve using the readings as vertical coordinates, and the EC of the antibody binding to recombinant human EGFR-His protein 50 It was analyzed using GraphPad Prism 6.0 software. The results are shown in Figure 1. The human-mouse chimeric antibody EGFR-mhPA8 had an EC50 of 128.7 ng / mL and R 2 It can effectively bind to recombinant human EGFR-His with a value of 1.000. The negative control H7N9-R1 failed to bind to the recombinant human EGFR-His protein.
[0111] In this example, the ability of EGFR-mhPA8 to block EGFR ligand-receptor binding was further analyzed using FACS. 3×10 5 10 μL of biotin-labeled EGF-Fc protein (source: Sino Biological, Inc.) with a final concentration of 217.1 nM was added to canine MDA-MB-468 cells. EGFR-mhPA8 antibodies with final concentrations of 306.74 nM, 102.25 nM, 34.08 nM, and 11.36 nM were added after incubation at 2 to 8°C for 30 minutes, and H7N9-R1 was used as a negative control antibody. The cells were mixed and incubated at 2 to 8°C for 20 minutes, then washed with PBS and centrifuged to remove unbound antibodies and ligands. Streptavidin-488-FITC secondary antibody (source: Sino Biological, Inc., hereinafter the same) was added and incubated at 2 to 8°C for 1 hour. Unconjugated secondary antibodies were removed by repeating washing and centrifugation. Finally, 200 μL of PBS was added to resuspend the cells, and the mixture was filtered through a 400 mesh filter into a flow tube, after which the pass-through was detected. The results are shown in Figure 2, and EGFR-mhPA8 can effectively block the binding of EGF-Fc protein to EGFR on MDA-MB-468 cells in a concentration gradient.
[0112] 1.2.2 Inhibition of MDA-MB-468 cell proliferation by murine antibodies
[0113] Breast cancer MDA-MB-468 cells highly express EGFR and also autoproduce various ligand factors of EGFR. In this example, the growth inhibitory function of a murine antibody against MDA-MB-468 cells was determined by the WST-8 assay.
[0114] 5 x 10⁶ MDA-MB-468 cells in a 96-well plate 3Cells were uniformly seeded per well. Cells were incubated in a CO2 incubator for 3 hours, and different concentrations of the murine antibody EGFR-mhPA8 (66.7 nM, 22.2 nM, 7.4 nM, 2.5 nM, 0.82 nM, 0.27 nM, 0.093 nM, 0.033 nM, and 0.013 nM) were added. A negative control group M (containing cells) and a blank control group B (containing only medium, no cells) were also used. Cells were incubated in a CO2 incubator at 37°C and 5% CO2 for 5 days, after which WST-8 was added at a rate of 15 μL per well. After 240 minutes of incubation, the OD was measured using a microplate reader. 450 - OD 630 The inhibition rate of the mouse-derived antibody was calculated as follows by measuring and subtracting the reading from detection blank well B: Inhibition Rate = (OD of Group M - OD of Sample) / (OD of Group M) × 100%. Quantitative efficacy curves were analyzed and plotted using GraphPad Prism software, with the horizontal axis representing antibody concentration and the vertical axis representing inhibition rate. As shown in Figure 3, EGFR-mhPA8 effectively inhibited the proliferation of MDA-MB-468, and the inhibition rate increased with increasing drug concentration on the "S" curve. EGFR-mhPA8 had an EC of 2.78 nM. 50 and R 2 MDA-MB-468 cells were inhibited by =0.991.
[0115] Example 2: Humanization of the murine antibody EGFR-mhPA8 and in vitro characterization of the humanized antibody
[0116] 2.1 Humanization and Production of Murine Antibody mhPA8
[0117] The nucleotide sequence of the EGFR-mhPA8 antibody was inferred to obtain the amino acid sequences of the heavy chain (sequence number: 8) and light chain variable region (sequence number: 9) of the EGFR-mhPA8 scFv antibody. The amino acid sequences of the three CDRs for the light and heavy chains of EGFR-mhPA8 scFv, respectively, were determined by referring to the Kabat
[26] and IMGT numbering approaches (see sequence numbers: 10-15). According to Kabat numbering, the three CDRs for the light and heavy chains, respectively, were transplanted in subsequent humanization steps and retained in the final humanized antibody EGFR-HPA8 scFv, with the exception of N at position 52 of LCDR2 being mutated to D.
[0118]
[0119] Humanization of murine antibodies was performed using the classical CDR transplantation method. [ 27,28 ]Antibodies possessing more than 50% amino acid sequence similarity with both the light and heavy chain variable regions of the murine antibody, and more than 50% amino acid sequence identity with the framework region of the light and heavy chain variable regions of the murine antibody to be modified, were selected as a humanization template library. The human antibody with the highest spatial similarity to the variable region of the antibody to be modified was selected as the humanization template. Three CDR sequences of the light or heavy chain of the murine antibody were substituted with the corresponding CDR amino acid sequences of the humanization template, and amino acids NG, NS, NA, and NT, which have a high risk of deamidation in the mutated sequences, were mutated to improve the chemical stability of the antibody and maintain its biological function. The affinity of the humanized antibodies was analyzed by ELISA, and humanized antibodies that maintained affinity were selected. In this embodiment, the humanization template used for the transplantation of the light chain variable region of EGFR-mhPA8 is IGKV1-NL1*01, which has 68.4% homology with the light chain of EGFR-mhPA8, and the humanization template for the heavy chain variable region is IGHV1-69-2*01, which has 64.9% homology with the heavy chain of EGFR-mhPA8. N52 of the humanization antibody LCDR2, which is prone to deamidation of the EGFR-HPA8 variable region, is mutated to D.
[0120] Since the key regions of the murine framework region are essential for maintaining the stability of the CDR spatial structure, said key regions must be reverse mutated to the corresponding amino acids of the murine antibody. According to Kabat numbering, the light chain was reverse mutated to Q at position 45, I at position 48, K at position 74, and D at position 76, and the heavy chain was reverse mutated to K at position 38, I at position 48, and L at position 70. The humanized antibody EGFR-HPA8 was obtained by CDR humanization grafting and frame region reverse mutation, and its heavy and light chain amino acid sequences are indicated as SEQ Nos: 22 / 23, respectively; The heavy and light chain amino acid sequences of the signal peptide are each denoted by SEQ ID NO: 24 / 25, and include the amino acid sequences of the sequentially linked heavy / light chain signal peptide (SEQ ID NO: 26 / 27), the heavy / light chain variable region of the humanized antibody (SEQ ID NO: 28 / 29), and the constant region of the humanized antibody, i.e., the IgG1 heavy chain constant region / human kappa light chain constant region (SEQ ID NO: 30 / 31); and the humanized CDR sequence described in detail in Table 2.
[0121]
[0122] A signal peptide-containing EGFR-HPA8 antibody light chain nucleotide sequence (SEQ No. 33) containing sequentially linked light chain signal peptide nucleotide sequences (SEQ No. 35), humanized antibody light chain variable region nucleotide sequences (SEQ No. 37), and human kappa light chain constant region nucleotide sequences (SEQ No. 39) was amplified by splicing PCR. The PCR product was amplified by an in-fusion method ( Hind III+XbaIt was inserted into the pSTEP2 vector (source: produced by Sinocelltech Limited, hereinafter the same) via double cleavage with I), and the correct plasmid was verified through sequencing. The nucleotide sequence of the heavy chain variable region of the EGFR-HPA8 antibody (Sequence No.: 36) was obtained by whole gene synthesis, and using the in-fusion method, it was inserted into the pSTEP2 vector containing the nucleotide sequence of the heavy chain signal peptide (Sequence No.: 34) and the nucleotide sequence of the heavy chain constant region of human IgG1 (Sequence No.: 38) ( Sca I + Nhe I. After double cleavage), the accurate EGFR-HPA8 light and heavy chain expression vectors were verified through sequencing. Plasmid extraction and HEK-293 cells ( fut8 After transfection with knockout, cells were cultured and expressed for 7 days. The cell supernatant was centrifuged and purified using affinity chromatography, and the chromatography medium was a protein A packing that interacts with Fc. After equilibrating the protein A chromatography column to 5 to 10 times the column volume with 50 mM Tris, 10 mM NaCl, and pH 8.0 buffer, the filtered culture supernatant was added to the chromatography column to bind it. The column was then filled to 5 to 10 times the column volume with 20 mM Tris, 0.3 M Arg, and pH 6.5 buffer, and the column was rinsed with 0.1 M Gly, 10 mM NaCl, and pH 3.5 elution buffer. The collected sample was neutralized with 2 M Tris (pH 8.0) to obtain high-purity and high-quality ADCC-enhanced EGFR-HPA8 antibodies.
[0123] Primer sequences for splicing PCR amplification of EGFR-HPA8 antibody light chains containing signal peptides
[0124]
[0125] Primer sequences for whole gene synthesis of the variable region of the EGFR-HPA8 antibody heavy chain
[0126]
[0127] 2.2 In Vitro Characterization of Humanized EGFR-HPA8 Antibody
[0128] 2.2.1 Humanized Antibody-Specific Binding and Ligand Competition Assay
[0129] Referring to Example 1.2.1, ELISA was performed with SCT200 (recorded in CN200610012002.8, hereinafter the same), Erbitux (MERCK, 201621, hereinafter the same), and a negative control to detect the binding ability of human antibodies to recombinant human EGFR protein. As shown in Fig. 4, EC for a humanized EGFR-HPA8 antibody that specifically binds to recombinant human EGFR-His 50 116.6 ng / mL, R 2 = 1.000 and; EC for SCT200 50 166.5 ng / mL, R 2 = 1.000; the EC50 for Erbitux is 253.6 ng / mL, R 2 = 1.000; and the negative control H7N9-R1 did not bind. The results indicated that EGFR-HPA8 had a superior ability to bind to recombinant human EGFR-his compared to SCT200 and Erbitux.
[0130] Meanwhile, the ability of the humanized antibody EGFR-HPA8 to block EGFR ligand-receptor binding was analyzed using FACS with SCT200, Erbitux, and a negative control set up, with reference to Example 1.2.1. The results are shown in Figure 5, and the ability of EGFR-HPA8 to block the binding of EGF-Fc protein to EGFR on MDA-MB-468 cells is stronger than that of SCT200 and Erbitux.
[0131] 2.2.2 Inhibition of the proliferation of various tumor cells by humanized antibodies
[0132] 2.2.2.1 Ability of Humanized Antibodies to Inhibit Cell Proliferation of MDA-MB-468
[0133] 5 x 10⁶ MDA-MB-468 cells in a 96-well plate 3 Cells were uniformly inoculated into wells. Cells were incubated in a CO2 incubator for 3 hours, and different concentrations of humanized antibody EGFR-HPA8 (666.7 nM, 222.2 nM, 74.1 nM, 24.7 nM, 8.23 nM, 2.74 nM, 0.91 nM, 0.31 nM, and 0.1 nM) were added, and SCT200 and Erbitux were used as controls. Subsequently, ligands were added, HB-EGF at a final concentration of 8 ng / mL (Source: Sino Biological, Inc., hereinafter the same), BTC-Fc at a final concentration of 200 ng / mL (Source: Sino Biological, Inc., hereinafter the same), or Fc-EREG at a final concentration of 1 μg / mL (Source: Sino Biological, Inc., hereinafter the same). Cells were incubated in a CO2 incubator at 37°C and 5% CO2 for 5 days, after which WST-8 was added at a rate of 15 μL per well. After 240 minutes of incubation, the OD was measured using a microplate reader. 450 - OD 630 The cell growth inhibition rate by the antibody was calculated by measuring [value]. The addition of a ligand without the antibody was used as Group M. Inhibition rate = (OD of Group M - OD of Sample) / (OD of Group M) × 100%. Quantitative efficacy curves were analyzed and plotted using GraphPad Prism software, where the horizontal axis represents antibody concentration and the vertical axis represents inhibition rate. The results are presented in Figure 6a and Table 3. EGFR-HPA8 demonstrated superior growth inhibition of MDA-MB-468 cells compared to SCT200 and the cetuximab control antibody under ligand-free conditions. Although EGFR-HPA8 exhibited a maximum inhibition rate similar to SCT200, the growth inhibition EC 50This was lower. The results of Example 2.2.1 show that the ability of EGFR-HPA8 to block the binding of EGF-Fc protein to EGFR on MDA-MB-468 cells was more potent than that of SCT200 and Erbitux. In this example, various ligands of EGFR were added to the MDA-MB-468 cell growth inhibition assay to further verify the ability of EGFR-HPA8 to block EGFR ligand-receptor binding at the cellular functional level. The results are presented in Figures 6b to 6d and Table 3. EGFR-HPA8 inhibited the proliferation of MDA-MB-468 cells more effectively than SCT200 and cetuximab under different ligand conditions.
[0134]
[0135] 2.2.2.2 Ability of Humanized Antibodies to Inhibit Fadu Cell Proliferation
[0136] Fadu is a human pharyngeal squamous cell carcinoma cell line that highly expresses EGFR and also autosecretes various EGFR ligand factors. Referring to Example 2.2.2.1, the inhibition of Fadu cell proliferation by the EGFR-HPA8 antibody under different ligand conditions (sources: Cell Resource Center, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences) was measured using the WST-8 assay. The results are presented in Figure 7 and Table 4. The growth inhibitory ability of EGFR-HPA8 on Fadu cells was similar to that of SCT200 and superior to cetuximab under ligand-free conditions, whereas the growth inhibitory ability of EGFR-HPA8 on Fadu cells was significantly superior to that of SCT200 and cetuximab under different ligand conditions. The results demonstrated that the EGFR-HPA8 antibody has a superior ability to inhibit EGFR ligand-receptor binding compared to SCT200 and cetuximab.
[0137]
[0138] 2.2.3 Effects of Humanized Antibody ADCC
[0139] In this example, a recombinant CD16a reporter gene system is used to detect the humanized antibody EGFR-HPA8-mediated ADCC effect. The recombinant CD16a reporter gene system includes effector cells Jurkat-NFAT-Luc2p-CD16A and target cells expressing EGFR. When the two cells are co-cultured and an EGFR antibody is added simultaneously, the Fab fragment of the EGFR antibody binds to EGFR expressed on the surface of the target cell, and its Fc fragment can bind to effector cells overexpressing Fcγ receptor CD16a, thereby activating the effector cells Jurkat-NFAT-Luc2p-CD16A and promoting NFAT-RE-mediated bioluminescence.
[0140] Target A431 cells (Source: Cell Resource Center, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences) were placed in 1 x 10⁻⁴ well plates of 96 cells. 4 Uniform inoculation was performed per well. After overnight incubation, antibodies of various concentrations (2.67 nM, 0.53 nM, 0.11 nM, 0.021 nM, 0.0043 nM, 0.00085 nM, 0.00017 nM, and 0.000034 nM) were added at a rate of 40 μL / well, followed by 1 × 10 5Canine effector cells Jurkat-NFAT-Luc2p-CD16A (Supplier: Sinocelltech Limited, hereinafter the same) were added at a rate of 40 μL / well, using three replicate wells for each assay. Target cell, effector cell, and negative antibody control wells were also used. Cells were incubated in a CO2 incubator at 37°C and 5% CO2 for 4 hours, and 20 μL / well of Passive Lysis 5× buffer was added. Cells were freeze-thawed once, and after shaking the plate, 20 μL of the supernatant per well was transferred to a 96-well white-bottom plate, and luminescence detection was performed using an LB960-Microplate Luminol Detector. Quantitative efficacy curves were analyzed and plotted using GraphPad Prism software; the horizontal axis represents the sample concentration, and the vertical axis represents the RLU value. Bioluminescence intensity induction multiplier = Sample RLU / Negative control RLU. The results are shown in Fig. 8, and EGFR-HPA8, the positive control Erbitux, and SCT200 can mediate effective ADCC effects on EGFR-expressing A431 tumor cells. Among these, EGFR-HPA8 showed an EC of 0.008 nM for the induction of ADCC. 50 and R 2 It had an advantage in half effective concentration and induction fold with a value of 0.999.
[0141] 2.3 Efficacy of EGFR-HPA-8 on tumors of mice subcutaneously xenografted with human gastric cancer cell line SNU-5 and human non-small cell lung cancer cell line NCI-H1975
[0142] SNU-5 cells in the logarithmic growth phase (ATCC Cell Bank) were washed with PBS, digested with 0.25% trypsin, and the digestate collected and centrifuged at 800 r / min for 5 minutes. The cells were resuspended in PBS, and the cell concentration was set to 5.0 x 10⁶ 7Adjusted to cells / mL (including 50% matrix gel). 5.0×10 6 100 μL of canine SNU-5 cell suspension was subcutaneously inoculated per mouse. The tumor volume was approximately 170 mm³. 3 After reaching [date], mice were randomly divided into 7 groups based on tumor volume, with 5 mice in each group. The drug was administered by intraperitoneal injection (IP) on the day of grouping and provided twice a week in 7 consecutive doses. The specific dosing regimen is presented in Table 5 below.
[0143]
[0144] The tumor growth inhibition value (TGI) was calculated as follows: T / C (%) = T RTV / C RTV Х 100%(T RTV is the RTV of the processing group; C RTV is the RTV of the negative control), Relative tumor volume RTV = V T / V0, V0 is the tumor volume measured on D0, the grouping and start date of medication, and V T is the tumor volume measured each time. TGI (%) = 1 - T / C (%).
[0145] All experimental animals were in good condition and showed slight body weight gain throughout the administration process. There was no significant difference in mouse body weight between each dosing group compared to the solvent control group. P > 0.05). The changes in body weight of all animals are presented in Figure 9 and Table 6.
[0146]
[0147] Tumor volume and TGI results for each group in the study are presented in Table 7 and Figure 10. 31 days after group administration, the mean tumor volume of the vehicle group was 559.9 ± 144.9 mm². 3 And the mean tumor volume of the positive control group of SCT200 low-dose 5 mpk was 317.1 ± 197.6 mm 3 was, and TGI was 44.3%, showing no significant difference from the vehicle group( P = 11.28%). The EGFR-HPA8 low-dose 5 mpk group had a tumor volume of 113.8 ± 74.0 mm³ 3 , and TGI 80.0%, a significant difference compared to the vehicle group ( P It showed superior efficacy (< 0.05), which demonstrates that EGFR-HPA8 exhibited slightly superior tumor suppression properties compared to the positive control SCT200 at this dose ( P = 0.09). The tumor volume of the positive control SCT200 20 mpk group was 191.8 ± 189.1 mm 3 was, and TGI was 66.5%, showing a significant difference from the vehicle group ( P < 0.05). The tumor volume of the EGFR-HPA8 high-dose 20 mpk group was 175.0 ± 175.0 mm 3 ..., and TGI was 68.9%, showing a significant difference from the vehicle group (P < 0.05). The EGFR-HPA8 and positive control SCT200 20 mpk groups showed a significant tumor suppression effect, and there was no significant difference in tumor volume between the two administration groups ( P = 0.9). In conclusion, the EGFR-HPA8 molecule showed significant antitumor efficacy at both 5 mpk and 20 mpk dose levels in the SNU-5 human gastric cancer xenograft tumor model, and the tumor suppression effect was slightly better than that of SCT200 at low doses.
[0148]
[0149] EGFR-HPA8 also showed a significant tumor-suppressing effect on tumors in a human non-small cell lung cancer cell line NCI-H1975 subcutaneous xenograft mouse model. NCI-H1975 cells were subcutaneously inoculated into the right dorsal side of Balb / c-nude mice (Cell Resource Center, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences), and grouping and administration are presented in Table 8.
[0150]
[0151] All experimental animals were in good condition and showed slight weight gain throughout the administration process, and there was no significant difference in mouse body weight between each administration group compared to the solvent control group. P > 0.05). The changes in body weight of all animals are presented in Fig. 11 and Table 9.
[0152]
[0153] Tumor volume and TGI results for each group in the study are presented in Table 10 and Figure 12. Eighteen days after grouping and administration, the positive control SCT200 and the high and low dose EGFR-HPA8 groups demonstrated significant tumor suppression effects and statistically significant differences in tumor volume between each administration group and the vehicle group. At 18 days, the mean tumor volume of the vehicle group was 1564.3 ± 529.0 mm². 3 The tumor volume after treatment with SCT200 5 mpk and EGFR-HPA8 5 mpk was 151.9 ± 99.1 mm², respectively. 3 and 86.5 ± 107.5 mm 3 The TGI rates were 90.4% and 94.5%, respectively. Tumor volumes after treatment with SCT200 20 mpk and EGFR-HPA8 20 mpk were 289.8 ± 321.4 mm², respectively. 3 and 149.3 ± 94.9 mm 3The TGI was 81.8% and 90.4%, respectively. At both 5 mpk and 20 mpk doses, EGFR-HPA8 showed slightly superior tumor suppression effects compared to the positive control SCT200, but there was no statistically significant difference. Taken together, these results suggest that the EGFR-HPA8 molecule has significant antitumor efficacy in the NCI-H1975 human non-small cell lung cancer xenograft tumor model.
[0154]
[0155] Example 3: Design and testing of EGFR antibody / TGFβR2 fusion protein containing various cleavage forms of TGFβR2
[0156] 3.1 Design, Protein Expression, and Purification of EGFR Antibody / TGFβR2 Fusion Protein Expression Vectors of Various Cleavage Forms of TGFβR2
[0157] This embodiment uses an anti-EGFR antibody as the targeting portion of the fusion protein and a TGFβR2 extracellular domain as the immunomodulatory portion of the fusion protein. The TGFβR2 extracellular domain is connected to the C-terminus of the EGFR antibody heavy chain by homologous recombination, and the EGFR antibody / TGFβR2 extracellular domain fusion protein (EGFR / TGFβR2) is formed by two chains, a light chain and a heavy chain. The structure of the fusion protein is illustrated in FIG. 13. Mass spectrometry results showed that there are multiple sensitive sites between the N-terminal 7-15 regions of the full-length TGFβR2 extracellular domain. To improve the structural stability of the fusion protein, the N-terminal amino acid sequence of the TGFβR2 extracellular domain was modified in this embodiment by deleting amino acid residues of varying numbers (Sequence Nos. 47-65). The EGFR antibody / TGFβR2 fusion protein is formed by linking the amino acid at the C-terminal heavy chain of the EGFR antibody to the extracellular domain of TGFβR2, which has a different amino acid deletion form, via a (G4S)4 linker (SEQ No.: 66). Additionally, the risk of protein degradation was reduced by removing the C-terminal lysine from the heavy chain of the EGFR antibody. A specific protocol for the design of the EGFR antibody / TGFβR2 fusion protein is presented in Table 11.
[0158]
[0159] In the above protocol, the target gene is amplified by PCR or Overlap-PCR, fused to an expression vector via in-fusion, and the plasmids are individually extracted after sequencing verification, and HEK-293 cells ( fut8 The cells were transiently delivered to a knockout chamber and cultured for 7 days. The supernatant was collected by centrifugation. After centrifugation, the cell supernatant was purified by protein A affinity chromatography to obtain the ADCC-enhanced EGFR antibody / TGFβR2 fusion protein.
[0160] 3.2 Degradation of EGFR antibody / TGFβR2 fusion protein containing various cleavage forms of TGFβR2
[0161] The purity and degradation of the expression products were analyzed by reduced SDS-PAGE. Other cleaved EGFR antibody / TGFβR2 fusion proteins 1-16 purified in Example 3.1 were subjected to reduced SDS-PAGE. Specific steps of the reduced SDS-PAGE: (1) SDS-PAGE preparation: 3.9% concentrated gel, 13% separated gel; (2) samples were boiled at 100°C for 2 minutes, centrifuged, and then sampled at 8 μg; (3) constant current of 40 mA, electrophoresis time of 1 hour. The results are shown in Fig. 14. The light chain molecular weight of the EGFR antibody / TGFβR2 fusion protein was approximately 25 KDa, the heavy chain molecular weight was approximately 66 KDa, and the molecular weight of the clipping species was 45 to 66 KDa. The results showed that while there were obvious clipping species in the extracellular domain of TGFβR2, fusion proteins of various truncated forms of the TGFβR2 extracellular domain had substantially fewer bands due to degradation than fusion proteins of the full-length form of the TGFβR2 extracellular domain. Therefore, the various truncated forms of the TGFβR2 extracellular domain prepared in the present invention significantly improved the stability of TGF-β receptor-containing antibody fusion proteins.
[0162] 3.3 Degradation Tendency of EGFR Antibody / TGFβR2 Fusion Protein Including Various Cleavage Forms of TGFβR2
[0163] 293E cell supernatants, which accelerate fusion protein processing, are used to further evaluate the stability of various cleavage forms of EGFR antibody / TGFβR2 fusion proteins. The 293E cell expression system, frequently used for antibody expression, expresses various host cell proteins (HCPs) and proteases necessary for cell growth. Therefore, antibody stability can be evaluated by observing the degradation tendency of the fusion protein in the supernatant of 293E cells.
[0164] The purified fusion protein was mixed with the supernatant of 293E cells cultured for 10 days at a volume ratio of 1:0.3, and the final concentration of the fusion protein was approximately 1 mg / mL. The mixed samples were shaken and thoroughly mixed, then incubated at 37°C for 48 hours. A control group incubated without cell supernatant was also used. The purity of the samples and the content of clipping species were detected by reduced SDS-PAGE, and the purity of the fusion protein heavy chains was calculated using BandScan software.
[0165] The test results are shown in Fig. 15, and the degradation rates of each sample are presented in Table 12. The results showed that the sheared body ratios of the TGFβR2 cleaved form fusion proteins (fusion proteins 2-16) in the control group were all less than 4.0%, which was significantly lower than the ratio of 24.8% for the TGFβR2 full-length form fusion protein (fusion protein 1). After incubation with the same cell supernatant at 37°C for 48 hours, all TGFβR2 full-length form fusion proteins (fusion protein 1) were cleaved at a rate of 100% in the experimental group. The truncated forms of TGFβR2 fusion proteins (fusion proteins 2-16) contained clipping species at different rates but were much better than the full-length control, with fusion proteins 2, fusion proteins 6, fusion proteins 9, fusion proteins 10, and fusion proteins 13 showing the best performance with a clipping species content of less than 3.0%.
[0166]
[0167] The above results indicate that EGFR antibody / TGFβR2 fusion proteins of various cleavage forms of TGFβR2 are more resistant to protease degradation than TGFβR2 fusion protein 1 in its full length form.
[0168] 3.4 Binding assay of EGFR antibody / TGFβR2 fusion protein against various cleavage forms of TGFβR2 against TGF-β
[0169] 100 ng / mL TGF-β1 and 40 ng / mL EGFR-His proteins were coated onto 96-well plates at a dose of 100 μL per well, respectively, overnight at 4°C. The plates were washed the following day, blocked at room temperature for 1 hour, and 100 μL of EGFR antibody / TGFβR2 fusion protein containing various cleavage forms of 2 μg / mL TGFβR2 was added per well. After incubating for 1 hour to remove unbound antibodies, the plates were washed, a secondary antibody, goat anti-hIgG Fc / HRP, was added, and the incubation and washing cycles were repeated. Finally, a substrate chromogenic solution was added to induce color development, and after completion, the OD was measured using a microplate reader. 450 The results were read. The results are shown in Figure 16. Although the binding abilities of EGFR antibody / TGFβR2 fusion proteins having various cleavage forms of TGFβR2 differed for TGF-β1, their binding abilities for EGFR were similar.
[0170] 3.5 Neutralization assay of EGFR antibody / TGFβR2 fusion protein against various cleavage forms of TGFβR2 against TGF-β
[0171] TGF-β regulates cellular function by controlling the transcription of various target genes. Plasminogen activator inhibitor-1 (PAI-1) is a key target downstream of the TGF-β1 / Smad signaling pathway, and activated Smad3 binds to the cis-acting element of the PAI-1 promoter region to regulate PAI-1 expression. The element containing the PAI-1 promoter region is inserted into a luciferase-containing vector in a specific form and delivered to HepG2 cells. In this reporter gene system, the addition of exogenous TGF-β protein initiates the expression of the luciferase reporter gene and initiates luminescence in the presence of a substrate. When an exogenous TGF-β antibody is added, it neutralizes the TGF-β protein, blocks TGF-β from binding to TGFβR2, inhibits the downstream signaling pathway, and ultimately suppresses the expression of the luciferase reporter gene. Therefore, the in vitro efficacy of a TGF-β antibody that neutralizes TGF-β can be determined by detecting the intensity of a light signal.
[0172] HepG2-3TP-Luc2p-puro cells (source: Sinocelltech Limited, hereinafter the same) were uniformly seeded into 96-well plates at a density of 30,000 cells / well. After overnight monolayer culture, the medium in the 96-well plates was discarded, replaced with DMEM medium containing 0.5% FBS, and incubated in a 5% CO2 incubator at 37°C for 6 hours. The medium in the 96-well plates was discarded, and 4 ng / mL TGF-β1 protein was added along with EGFR antibody / TGFβR2 fusion protein at a final concentration of 0.02 μg / ml, and incubated in a 5% CO2 incubator at 37°C for 18 hours. The negative control M group (containing cells and TGF-β1) and the negative control M' group (containing cells without TGF-β1) were used simultaneously. Finally, 5 × 200 µL of lysis buffer was added, 10 μL of the cell sample was taken to detect the bioluminescence intensity value (RLU), and the neutralization rate of the EGFR antibody / TGFβR2 fusion protein was calculated. Neutralization rate (%) = (RLU value of group M - RLU value of sample) / (OD value of group M - OD value of group M') × 100%. The antibody concentration was used as the horizontal axis and the antibody neutralization rate as the vertical axis, and the quantitative efficacy curve was analyzed and plotted using GraphPad Prism software. As shown in Fig. 17, EGFR antibody / TGFβR2 fusion proteins 2, fusion protein 6, fusion protein 8, fusion protein 13, fusion protein 14, and fusion protein 16 containing truncated forms of TGFβR2 had a specific ability to neutralize TGF-β1, and among these, fusion protein 2 showed a neutralizing ability similar to fusion protein 1 containing the full-length form of TGFβR2, whereas fusion proteins 5, fusion protein 6, and fusion protein 8 showed a superior neutralizing ability to fusion protein 1 at this concentration.Fusion protein 6 had the strongest ability to neutralize TGF-β1. The remaining EGFR antibody / TGFβR2 fusion proteins, including the cleaved form of TGFβR2, essentially had no or weak neutralizing ability.
[0173] The TGF-β3 protein has a high affinity for TGFβR2 and can activate TGF-β downstream signaling. The ability of the fusion proteins to neutralize TGF-β3 (final concentration 20 ng / mL) was analyzed by applying a reporter gene system in this example. The results are shown in Fig. 18. Fusion proteins 2, 4, and 13 showed TGF-β3 neutralizing ability similar to fusion protein 1, whereas fusion proteins 3, 5, 6, and 8 had superior TGF-β3 neutralizing ability compared to fusion protein 1. Fusion protein 6 also had the strongest ability to neutralize TGF-β3.
[0174] Based on the above analysis of the stability and neutralizing ability of fusion proteins including TGFβR2 cleaved forms, the present invention prefers TGFβR2 cleaved forms of fusion proteins 2 to 6, 8, 13, 14, and 16, more preferably TGFβR2 cleaved forms of fusion proteins 2, 5, 6, and 8, and most preferably TGFβR2 cleaved forms of fusion protein 6.
[0175] Example 4: In vitro biological characteristics of Fusion Protein 6, an EGFR antibody / TGFβR2 cleavage form fusion protein.
[0176] 4.1 Assay of EGFR Antibody / TGFβR2 Fusion Protein Binding Ability
[0177] 4.1.1 EGFR Antibody / TGFβR2 Fusion Protein Binding and Competitive Characteristics against TGF-β
[0178] TGF-β1 and TGF-β3 proteins at a final concentration of 2 μg / mL were coated onto 96-well plates at a rate of 100 μL per well, respectively, and incubated overnight at 4°C. The next day, the plates were washed, blocked at room temperature for 1 hour, and incubated for 1 hour with EGFR antibody / TGFβR2 fusion protein 6 at various concentrations (1.22 pM, 4.88 pM, 19.53 pM, 78.13 pM, 312.5 pM, 1250 pM, 500 pM, 2000 pM). Subsequently, the plates were washed to remove unbound antibodies, and the secondary antibody, goat anti-hIgG 50 2 Incubate with F(ab)2 / HRP, repeat washing, add substrate colorimetric solution to induce color development, and after completion, check the OD using a microplate reader. 450 The results were read. The results are shown in Fig. 19. The binding ability of fusion protein 6 to TGF-β1 and TGF-β3 proteins was similar to that of fusion protein 1, and the EC for binding with TGF-β1 protein 50 This is 91 pM and R 2 =0.998, and the EC for binding with TGFβ3 protein 50 This is 102 pM, and R 2 =0.998.
[0179] In this example, the ability of fusion protein 6 to compete with TGF-β1 protein or TGF-β3 protein for binding to TGFβR2-Fc protein at the protein level is further analyzed.
[0180] TGF-β1 protein or TGF-β3 protein at a final concentration of 0.2 μg / mL or 0.5 μg / mL was coated onto 96-well plates at 100 μL per well overnight at 4°C. The next day, the plates were washed, blocked at room temperature for 1 hour, and 100 μL of biotin-labeled TGFβR2-Fc protein (protein source: biotin-labeled by Sino Biological, Inc. and Sinocelltech Limited, hereinafter the same) at a final concentration of 0.2 μg / mL (TGF-β1 competition) or 1 μg / mL (TGF-β3 competition) was added to 100 μL of EGFR antibody / TGFβR2 fusion protein at different concentrations (0.05 nM, 0.14 nM, 0.42 nM, 1.25 nM, 3.75 nM, 11.24 nM, 33.71 nM, 101.12 nM). Positive control wells containing only TGFβR2-Fc protein were also used. After incubating for 1 hour, the plate was washed, the secondary detection antibody streptavidin / HRP was added, and after incubating for 1 hour, the plate was washed repeatedly. Finally, the substrate chromogenic solution was added to induce color development, and after completion, the OD was measured using a microplate reader. 450 The competitive inhibition rate PI% of the fusion protein was OD 450 Calculated based on the value, inhibition rate PI(%) = (OD of positive wells) 450 Value - OD of the sample well 450 Value) / OD of positive well 450 The value is × 100%. The result is shown in Fig. 20, and fusion protein 6 has a binding blocking ability of TGF-β1 protein or TGF-β3 protein to TGFβR2-Fc similar to that of fusion protein 1.
[0181] 4.1.2 Binding Characteristics of EGFR Antibody / TGFβR2 Fusion Protein Against EGFR
[0182] Referring to Example 1.2.1, the binding ability of the fusion protein to the recombinant human EGFR protein was measured by ELISA. As shown in Fig. 21, the binding ability of fusion protein 6 to EGFR and its ability to compete with EGF for binding to EGFR were measured by binding EC 50 This is 133.1 ng / mL, and R 2 = 1.000, which was similar to EGFR-HPA8.
[0183] 4.2 EGFR Antibody / TGFβR2 Fusion Protein Binding Affinity Assay
[0184] In this example, the affinity of binding of the EGFR antibody / TGFβR2 fusion protein to biotinylated recombinant human EGFR protein and TGF-β1 protein was determined using a biomolecular interaction analysis system (model: OctetRED96e, manufacturer: Fortebio) using EGFR-HPA8 and H7N9-R1, respectively, as negative controls. Affinity parameters were derived by fitting multi-concentration point binding and dissociation curves, the results of which are presented in Tables 13 and 14, and specific kinetic characteristic parameter curves are shown in Figures 22 and 23.
[0185] The results showed that fusion protein 6 maintained a higher binding affinity for human EGFR protein compared to the monoclonal antibody EGFR-HPA8, where the KD value was 8.77 pM and the binding constant k on The value is 1.68E+06 M -1 s -1 and, dissociation constant k dis is 1.47E-05 s -1 ...is. In addition, the cleaved form of TGFβR2 fusion protein 6 has an affinity for human EGFR protein similar to that of the full-length form of TGFβR2 fusion protein 1, where k D The value is 96.1 pM, and the coupling constant kon The value is 1.53E+06 M -1 s -1 and, dissociation constant k dis is 1.47E-04 s -1 am.
[0186]
[0187]
[0188] The above results indicate that fusion protein 6 has good affinity for both human EGFR and TGF-β1.
[0189] 4.3 Evaluation of EGFR antibody / TGFβR2 fusion protein neutralizing TGF-β
[0190] Since TGF-β1 can inhibit the proliferation of Mv-1-1u cells, the ability of the EGFR antibody / TGFβR2 fusion protein to neutralize TGF-β1 can be detected using the WST-8 assay.
[0191] 1 x 10⁴ Mv-1-lu cells (Source: Cell Resource Center, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences) per well in a 96-well plate 3Cells were uniformly inoculated at a density of 50 μL per well. Cells were incubated in a CO2 incubator for approximately 3 hours to adhere to the well walls, after which EGFR antibody / TGFβR2 fusion protein samples at various concentrations (0.0078 nM, 0.0156 nM, 0.0313 nM, 0.0625 nM, 0.125 nM, 0.25 nM, 0.5 nM, 1 nM, 2 nM) diluted in 1640 medium containing 10% FBS were added at a dose of 50 μL per well. Finally, factor TGF-β1 at a final concentration of 1 ng / mL was added at a dose of 10 μL per well. A positive control group M (containing cells and TGF-β1), a negative control group M' (containing cells without TGF-β1), and a blank control group B (with only culture medium added without cells) were also used. After incubating the cells in a CO2 incubator at 37°C and 5% CO2 for 5 days, 10 μL of WST-8 was added per well. The samples were left for 180 minutes, and the OD was measured using a microplate reader. 450 -OD 630The readings were measured, and the neutralization rate of the EGFR antibody / TGFβR2 fusion protein was calculated by subtracting the readings of the blank control B. Neutralization rate (%) = (OD of group M' - OD of sample) / (OD of group M' - OD of group M) × 100%. Quantitative efficacy curves were analyzed and plotted using GraphPad Prism software, where the horizontal axis represents antibody concentration and the vertical axis represents inhibition rate. As shown in Figure 24, the control product H7N9-R1-43-IgG1(L9) of fusion protein 6 and TGFβR2 (source: Sinocelltech Limited for biotin labeling, hereinafter the same) was able to effectively neutralize the inhibition of Mv-1-lu proliferation by TGF-β1 in a dose-dependent manner, and the half-effective concentration of fusion protein 6 was lower than that of the control product H7N9-R1-43-IgG1(L9), indicating that the neutralization activity of the said molecule is superior. EGFR-HPA8 did not neutralize TGF-β1, which suggests that the TGFβR2 portion of fusion protein 6 is responsible for the neutralizing effect on TGF-β1.
[0192] The ability of fusion protein 6 to neutralize TGF-β was further analyzed in this example using a reporter gene system with reference to Example 3.5. The results are shown in Fig. 25, and while both fusion protein 6 of TGFβR2 and the control product H7N9-R1-43-IgG1(L9) were able to effectively neutralize TGF-β1 in a dose-dependent manner, the maximum neutralization rate of fusion protein 6 (74.8%) was much higher than that of the control product H7N9-R1-43-IgG1(L9) (55.3%), which further demonstrated the superior neutralization activity of fusion protein 6.
[0193] 4.4 Evaluation of the Cell Proliferation Inhibitory Activity of EGFR Antibody / TGFβR2 Fusion Protein
[0194] The inhibition of EGFR antibody / TGFβR2 fusion protein on the growth of MDA-MB-468 cells was evaluated using the WST-8 method according to Example 1.2.2 to determine its EGFR portion characteristics. As shown in Figure 26, the ability of fusion protein 6 to inhibit the proliferation of MDA-MB-468 cells was similar to that of EGFR-HPA8, and the inhibition rate increased with increasing drug concentration on the "S" curve. The control product H7N9-R1-43-IgG1(L9), which has TGFβR2 function, did not inhibit the proliferation of MDA-MB-468 cells, which demonstrates that fusion protein 6 inhibited the proliferation of tumor cells by its EGFR portion.
[0195] 4.5 ADCC Effects of EGFR Antibody / TGFβR2 Fusion Protein
[0196] The ADCC effect mediated by the EGFR antibody / TGFβR2 fusion protein on EGFR-expressing cells was evaluated with reference to Example 2.2.3. The results are shown in Fig. 27. In the concentration range of 0.00004 to 3 nM, fusion protein 6 and the anti-EGFR antibody EGFR-HPA8 can mediate a similar ADCC effect on EGFR-expressing tumor cells A431. The control product H7N9-R1-43-IgG1(L9), which has TGFβR2 function, had no ADCC effect on A431 cells, which demonstrates that the EGFR portion of fusion protein 6 mediates the ADCC function in this experimental system.
[0197] Example 5: Pharmacodynamic study of TGFβR2 cleaved form (fusion protein 6) EGFR antibody / TGFβR2 fusion protein in NCI-H1975 subcutaneous transplant tumor model
[0198] 1×10 on the right side of the thorax of the Balb / c-nu mouse 6 NCI-H1975 cells were subcutaneously inoculated. The tumor volume was approximately 300 mm³ 3When [the target] was reached, animals were randomly grouped into groups of six based on tumor volume and administered. Drug administration began on the day of grouping and consisted of 10 consecutive doses administered via intraperitoneal injection (IP) twice a week, and the drug was discontinued after the last dose to monitor for tumor recurrence. The specific drug regimen is presented in Table 15 below.
[0199]
[0200] The animals in each group were in generally good condition regarding activity and feeding during the administration process, and their body weight also increased to some extent. After administration, there was no significant difference in body weight between the treatment group and the solvent control group. P > 0.05). The changes in body weight of all animals are presented in Table 16 and Figure 28.
[0201]
[0202] The tumor volume results for each group in the above test are presented in Table 17 and Figure 29. After 35 days of treatment by group, the average tumor volume of the solvent control group was 7150.78 ± 780.4 mm 3 5 out of 6 mice in the fusion protein 6 administration group showed complete tumor remission (CR), with an average tumor volume of 4.55 ± 4.55 mm. 3 The TGI was 99.9%, which was significantly different from the solvent control group (P < 0.001). In contrast, only one mouse in the EGFR-HPA8 administration group showed complete tumor remission, with an average tumor volume of 79.44 ± 28.65 mm². 3 And, the TGI was 98.9%. The results showed that fusion protein 6 exhibited a significant inhibitory effect on NCI-H1975 non-small cell lung cancer subcutaneous graft tumors, and indicated that the tumor-suppressing effect was superior to EGFR-HPA8 at the same molar dose ( P = 0.237).
[0203]
[0204] Example 6: Stability analysis of EGFR antibody / TGFβR2 fusion protein with cleaved form of TGFβR2 (fusion protein 6)
[0205] 6.1 Analysis of Ultrafiltration Stability of EGFR Antibody / TGFβR2 Fusion Protein
[0206] EGFR antibody / TGFβR2 fusion protein samples were concentrated to a concentration of approximately 10 mg / mL by ultrafiltration in a buffer of 100 mM glycine, 10 mM NaCl, 50 mM Tris, and pH 7.5. The purity and stability of the ultrafiltered samples were tested using reduced SDS-PAGE and molecular sieve chromatography (SEC-HPLC, Agilent 1260 liquid chromatography system, TSK-G3000SWXL column). The EC-HPLC operating steps were: (1) mobile phase: 200 mM NaH2PO4, 100 mM arginine, pH 6.5; (2) loading volume was 80 μg; (3) analysis time was 30 min, flow rate was 0.5 mL / min, and column temperature was 25℃; and (4) purity was calculated according to the peak area normalization method.
[0207] The results of the purity test after sample concentration are shown in Fig. 30, and the sample purity and fragment ratios are presented in Table 18. The results showed that TGFβR2 cleaved fusion protein 6 is less likely to be destroyed after concentration and has higher ultrafiltration stability compared to the full-length TGFβR2 fusion protein.
[0208]
[0209] 6.2 Analysis of Thermal Stability of EGFR Antibody / TGFβR2 Fusion Protein
[0210] The thermal stability of the sample was measured by differential scanning fluorescence (DSF) using the UNcle system (Unchained Labs, model: UNCLE-0330). Working steps: (1) the sample volume was 9 μL; (2) the experimental parameters were set as follows: the temperature range was 25°C to 95°C, and the heating rate was 0.3°C / min; (3) the data were analyzed using UNcle analysis software, and the median of the internal fluorescence change curve under UV266 was set to Tm, and the aggregation onset temperatures of the aggregation change curve formed by static light scattering signals under UV266 / Blue473 were set to Tagg266 and Tagg473.
[0211] The results of the thermal stability test of fusion protein 6 are presented in Table 19, which showed excellent thermal stability.
[0212]
[0213] 6.3 Analysis of Thermal Accelerated Stability of EGFR Antibody / TGFβR2 Fusion Protein
[0214] After storing the sample at 45°C for one week, the accelerated stability of the sample was analyzed by SEC-HPLC and SDS-PAGE, and the procedure was the same as in 6.1.
[0215] The results of the thermal accelerated stability of fusion protein 6 are presented in Table 20. After storage at 45°C for one week, the SEC purity of fusion protein 6 decreased by 0.7% but remained high, aggregate levels increased less, and fragment levels remained unchanged, indicating excellent thermal accelerated stability.
[0216]
[0217] 6.4 Analysis of Freeze-Thaw Stability of EGFR Antibody / TGFβR2 Fusion Protein
[0218] The samples were subjected to five repeated freeze-thaw cycles, in which they were stored at -80°C for 3 hours and then thawed at 45°C for 1 hour. The freeze-thaw stability of the samples was analyzed by SEC-HPLC, and the procedure was the same as in 6.1.
[0219] The freeze-thaw stability results of fusion protein 6 are presented in Table 21. After repeating freeze-thaw cycles five times, the SEC purity of fusion protein 6 did not change significantly, and the levels of aggregates and fragments did not increase significantly, indicating excellent freeze-thaw stability.
[0220]
[0221] 6.5 Shaking Stability of EGFR Antibody / TGFβR2 Fusion Protein
[0222] The samples were placed in deep well plates and shaken on a vortex shaker at 800 rpm for 24 hours. The samples were analyzed by SEC-HPLC according to the same procedure as in 6.1. The results are presented in Table 22, indicating that the SEC monomer purity of the samples did not change significantly after 24 hours of shaking and that the levels of aggregates and fragments did not increase significantly, which demonstrates that fusion protein 6 has excellent shaking stability.
[0223]
[0224] Example 7: Design and Characterization of Solid Tumor Antigen-Targeting Antibody X / TGFβR2 Fusion Protein in Which the TGFβR2 Mole Is the Cleaved Form of TGFβR2 (Fusion Protein 6)
[0225] 7.1 Design, Expression, and Purification of TGFβR2 × Antibody / Cleaved TGFβR2 Fusion Protein Expression Vector
[0226] To further verify the structural stability and ability to neutralize TGF-β1 of the cleaved form of TGFβR2 selected in Example 3.2, this example uses various solid tumor antigens as the targeting portion of the fusion protein and the TGFβR2 extracellular domain (full length and ECD deletion (6-26) fusion protein 6) as the immunomodulatory portion of the fusion protein to form an X antibody / TGFβR2 extracellular domain fusion protein (X / TGFβR2 fusion protein). Similarly, in the X / TGFβR2 fusion protein, the C-terminal amino acid of the X antibody heavy chain is linked to the TGFβR2 extracellular domain via a (G4S)4 linker. Additionally, the C-terminal lysine of the X antibody heavy chain was removed to reduce the risk of proteolytic cleavage. The production protocol for the X / TGFβR2 fusion protein is presented in Table 23.
[0227]
[0228] PCR or nested-PCR amplifies the target gene and links it to an expression vector via in-fusion. The recombinant expression vector is validated by sequencing, and the plasmid is extracted and applied to HEK-293 cells ( fut8 The cells were temporarily delivered to the knockout stage, cultured for 7 days, and the supernatant was collected by centrifugation. The fusion protein was purified by protein A affinity chromatography of the obtained cell supernatant.
[0229] 7.2 X Antibody / Degradation of Cleaved TGFβR2 Fusion Protein
[0230] The purity as well as the degradation of the X / TGFβR2 fusion protein was analyzed by reduced SDS-PAGE. The results are shown in Figure 31. For various X / TGFβR2 fusion proteins, samples expressing the selected cleavage form of the TGFβR2 extracellular domain were much more stable and had fewer degradation bands than control samples with the full-length TGFβR2 extracellular domain. The stability of the samples must be attributed to the currently cleavage form of the TGFβR2 extracellular domain, regardless of the type of targeting part, i.e., the antibody used.
[0231] 7.3 X Antibody / Cleaved TGFβR2 Fusion Protein Degradation Tendency
[0232] In this example, 293E cell supernatant was used for accelerated treatment of the fusion protein, and the degradation stability of the X / TGFβR2 fusion protein having a selected cleaved TGFβR2 extracellular domain was further determined as in Example 3.3. The results of the sample purity test are shown in Fig. 32, and the sample purity and the percentage of sheared bodies are presented in Table 24. The results indicate that the X / TGFβR2 fusion protein having the preferred TGFβR2 extracellular domain cleavage form is more resistant to protease degradation than the full-length form of the TGFβR2 fusion protein.
[0233]
[0234] To verify the stability of an X / TGFβR2 fusion protein having a selected cleaved TGFβR2 extracellular domain under specific concentration conditions, its ultrafiltration stability was analyzed using the method of Example 6.1. The results are presented in Table 25. The X / TGFβR2 fusion protein having a preferred cleaved extracellular domain of TGFβR2 does not degrade easily after concentration, and has a clipping species content of less than 4.0% (SDS-PAGE purity), and has stronger ultrafiltration stability than an X / TGFβR2 fusion protein having a full-length extracellular domain of TGFβR2.
[0235]
[0236] In summary, the excellent stability of fusion proteins containing a desirable truncated TGFβR2 extracellular domain was further verified by fusion proteins using various types of solid tumor antigens as targeting sites.
[0237] Example 8: In vitro biological characteristics of an X / TGFβR2 fusion protein having cleaved TGFβR2 (fusion protein 6) and targeting a solid tumor antigen as the targeting portion
[0238] 8.1 X / TGFβR2 Fusion Protein Binding TGF-β1 Assay
[0239] The binding ability of the X / TGFβR2 fusion protein to TGF-β1 was measured by ELISA according to Example 3.4. As shown in Fig. 33, the ability of the X / TGFβR2 fusion protein having a preferred cleavage form of TGFβR2 to bind to TGF-β1 is slightly lower than the ability of the X / TGFβR2 fusion protein having TGFβR2 in its full length form.
[0240] 8.2 TGF-β Neutralization assay by X / TGFβR2 fusion protein
[0241] The ability of the X / TGFβR2 fusion protein to neutralize TGF-β1 and TGF-β3 was tested with reference to Example 3.5. As shown in Fig. 34, the ability of the X / TGFβR2 fusion protein having a preferred truncated form of TGFβR2 to neutralize both TGF-β1 and TGF-β3 was superior to the ability of the X / TGFβR2 fusion protein having a full-length form of TGFβR2.
[0242] 8.3 Binding assay of X / TGFβR2 fusion protein to targets of the X portion
[0243] X partial target antigens ERBB2-his, VEGF165, VEGFR2-His, CTLA4-his, and EGFR-His, with final concentrations of 10 ng / mL, 5 ng / mL, 80 ng / mL, 80 ng / mL, and 40 ng / mL, respectively, were coated onto 96-well plates at a rate of 100 μL per well. The plates were coated overnight at 4°C. The following day, the plates were washed, blocked at room temperature for 1 hour, and incubated for 1 hour with 100 μL of X / TGFβR2 fusion protein at a final concentration of 13.89 nM. The plates were washed to remove unbound antibodies, incubated with the secondary antibody goat anti-hIgG Fc / HRP, and the washing process was repeated. Finally, a substrate chromogenic solution was added to induce color development, and after completion, the OD was measured using a microplate reader. 450 The X / TGFβR2 fusion protein having selected truncated TGFβR2 had a similar ability to bind to the corresponding antigen on the X side as the X / TGFβR2 fusion protein containing the full-length form of TGFβR2. As shown in Fig. 35, the X / TGFβR2 fusion protein having selected truncated TGFβR2 had a similar ability to bind to the corresponding antigen on the X side as the X / TGFβR2 fusion protein containing the full-length form of TGFβR2.
[0244] Sequence list
[0245]
[0246]
[0247]
[0248]
[0249]
[0250]
[0251]
[0252]
[0253]
[0254]
[0255]
[0256]
[0257]
[0258]
[0259]
[0260]
[0261]
[0262]
[0263]
[0264]
[0265]
[0266]
[0267]
[0268]
[0269]
[0270]
[0271]
[0272]
[0273]
[0274]
[0275]
[0276]
[0277]
[0278]
[0279]
[0280]
[0281]
[0282]
[0283]
[0284]
[0285]
[0286]
[0287]
[0288]
[0289]
[0290]
[0291]
[0292]
[0293]
[0294]
[0295]
[0296]
[0297]
[0298]
[0299]
[0300]
[0301]
[0302]
[0303]
[0304]
[0305]
[0306]
[0307]
[0308]
[0309]
[0310]
[0311]
[0312]
[0313]
[0314]
[0315]
[0316]
[0317]
[0318]
[0319]
[0320]
[0321]
[0322]
[0323]
[0324]
[0325]
[0326] References
[0327] 1. Xie, F., et al., TGF-beta signaling in cancer metastasis. Acta Biochim Biophys Sin (Shanghai), 2018. 50 (1): p. 121-132.
[0328] 2. Colak, S. and P. Ten Dijke, Targeting TGF-beta Signaling in Cancer. Cancer Trends, 2017. 3 (1): p. 56-71.
[0329] 3. Fabregat, I., et al., TGF-beta signaling in cancer treatment. Curr Pharm Des, 2014. 20 (17): p. 2934-47.
[0330] 4. Batlle, E. and J. Massague, Transforming Growth Factor-beta Signaling in Immunity and Cancer. Immunity, 2019. 50 (4): p. 924-940.
[0331] 5. Laskin, JJ and AB Sandler, Epidermal growth factor receptor: a promising target in solid tumours. Cancer treatment reviews, 2004. 30 (1): p. 1-17.
[0332] 6. Hynes, N., et al., The ErbB receptor tyrosine family as signal integrators. Endocrine-related cancer, 2001. 8 (3): p. 151-159.
[0333] 7. Zandi, R., et al., Mechanisms for oncogenic activation of the epidermal growth factor receptor. Cellular signaling, 2007. 19 (10): p. 2013-2023.
[0334] 8. Seshacharyulu, P., et al., Targeting the EGFR signaling pathway in cancer therapy. Expert opinion on therapeutic targets, 2012. 16 (1): p. 15-31.
[0335] 9. Zhao, Y., et al., TGF - β transactivates EGFR and facilitates breast cancer migration and invasion through canonical Smad3 and ERK / Sp1 signaling pathways. Molecular oncology, 2018. 12 (3): p. 305-321.
[0336] 10. Wendt, M.K., J.A. Smith, and W.P. Schiemann, Transforming growth factor-β-induced epithelial-mesenchymal transition facilitates epidermal growth factor-dependent breast cancer progression. Oncogene, 2010. 29 (49): p. 6485.
[0337] 11. Lee, E., et al., Transforming growth factorβ1 transactivates EGFR via an H2O2-dependent mechanism in squamous carcinoma cell line. Cancer letters, 2010. 290 (1): p. 43-48.
[0338] 12. Dunfield, L.D. and M.W. Nachtigal, Inhibition of the antiproliferative effect of TGFβ by EGF in primary human ovarian cancer cells. Oncogene, 2003. 22 (30): p. 4745.
[0339] 13. Kretzschmar, M., et al., A mechanism of repression of TGFβ / Smad signaling by oncogenic Ras. Genes & development, 1999. 13 (7): p. 804-816.
[0340] 14. ten Dijke, P., K. Miyazono, and C.-H. Heldin, Signaling inputs converge on nuclear effectors in TGF-β signaling. Trends in biochemical sciences, 2000. 25 (2): p. 64-70.
[0341] 15. Funaba, M., C.M. Zimmerman, and L.S. Mathews, Modulation of Smad2-mediated signaling by extracellular signal-regulated kinase. Journal of Biological Chemistry, 2002. 277 (44): p. 41361-41368.
[0342] 16. Richter, P., et al., EGF / TGFbeta1 co-stimulation of oral squamous cell carcinoma cells causes an epithelial-mesenchymal transition cell phenotype expressing laminin 332. J Oral Pathol Med, 2011. 40 (1): p. 46-54.
[0343] 17. Uttamsingh, S., et al., Synergistic effect between EGF and TGF-beta1 in inducing oncogenic properties of intestinal epithelial cells. Oncogene, 2008. 27 (18): p. 2626-34.
[0344] 18. Xu, Z., et al., TGFbeta and EGF synergistically induce a more invasive phenotype of epithelial ovarian cancer cells. Biochem Biophys Res Commun, 2010. 401 (3): p. 376-81.
[0345] 19. Xiong, J., et al., Epidermal growth factor promotes transforming growth factor-beta1-induced epithelial-mesenchymal transition in HK-2 cells through a synergistic effect on Snail. Mol Biol Rep, 2014. 41 (1): p. 241-50.
[0346] 20. Buonato, J.M., I.S. Lan, and M.J. Lazzara, EGF augments TGFbeta-induced epithelial-mesenchymal transition by promoting SHP2 binding to GAB1. J Cell Sci, 2015. 128 (21): p. 3898-909.
[0347] 21. Wang, T., et al., The TGFβ-miR-499a-SHKBP1 pathway induces resistance to EGFR inhibitors in osteosarcoma cancer stem cell-like cells. Journal of Experimental & Clinical Cancer Research, 2019. 38 (1): p. 226.
[0348] 22. Jie, H.B., et al., CTLA-4(+) Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis. Cancer Res, 2015. 75 (11): p. 2200-10.
[0349] 23. Bedi, A., et al., Inhibition of TGF-beta enhances the in vivo antitumor efficacy of EGF receptor-targeted therapy. Mol Cancer Ther, 2012. 11 (11): p. 2429-39.
[0350] 24. Zhang, Y., et al., The canonical TGF-beta / Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer. Respir Res, 2019.20 (1): p. 164.
[0351] 25. Jones, S.T. and M.M. Bendig, Rapid PCR-cloning of full-length mouse immunoglobulin variable regions. Biotechnology (N Y), 1991. 9 (6): p. 579.
[0352] 26. Kabat, E.A., et al., Sequences of proteins of immunological interest . 1992: DIANE publishing.
[0353] 27. Jones, P.T., et al., Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature, 1986. 321 (6069): p. 522.
[0354] 28. Verhoeyen, M. and L. Riechmann, Engineering of antibodies. BioEssays, 1988. 8 (2 - 3): p. 74-78.
Claims
Claim 1 Sequence No.: A cleaved TGFβR2 extracellular domain molecule consisting of an amino acid sequence of 52. Claim 2 A fusion protein comprising the truncated TGFβR2 extracellular domain molecule described in claim 1. Claim 3 In paragraph 2, the fusion protein comprises: a) the cleaved TGFβR2 extracellular domain molecule described in paragraph 1; and b) a targeting portion. Claim 4 A fusion protein according to paragraph 3, wherein the targeting portion is a cancer cell-specific targeting portion selected from an antibody or its antigen-binding fragment; a functional ligand or its Fc fusion protein; and a receptor protein or its Fc fusion protein. Claim 5 In paragraph 4, the fusion protein wherein the targeting portion is an anti-EGFR antibody or an antigen-binding fragment thereof. Claim 6 A fusion protein in which, in paragraph 3, the N-terminus of the cleaved TGFβR2 extracellular domain molecule is connected to the C-terminus of the heavy chain of the targeting portion. Claim 7 A fusion protein according to paragraph 3, wherein the N-terminus of the cleaved TGFβR2 extracellular domain molecule is connected to the C-terminus of the heavy chain of the targeting portion via a linker. Claim 8 A fusion protein according to claim 7, wherein the linker is a G4S flexible peptide linker or a (G4S)4 peptide linker. Claim 9 (a) a heavy chain variable region comprising heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3 domains, each consisting of SEQ Nos: 19, 20, and 21, and (b) a light chain variable region comprising light chain CDR1, light chain CDR2, and light chain CDR3 domains, each consisting of SEQ Nos: 16, 17, and 18, an isolated antibody or antigen-binding fragment thereof that binds to EGFR. Claim 10 In claim 9, the antibody or its antigen-binding fragment comprises: (a) a heavy chain variable region comprising a sequence comprising SEQ ID NO: 28; and (b) a light chain variable region comprising a sequence comprising SEQ ID NO:
29. Claim 11 In claim 9, the antibody further comprises: (a) a heavy chain constant region comprising a sequence comprising SEQ ID NO: 30; and (b) a light chain constant region comprising a sequence comprising SEQ ID NO: 31, an antibody or an antigen-binding fragment thereof. Claim 12 A fusion protein, wherein the targeting portion is selected from the anti-EGFR antibody described in claim 9, trastuzumab, bevacizumab, ramucirumab, ipilimumab, or panitumumab. Claim 13 In claim 6, the fusion protein comprises: (a) an amino acid sequence of a heavy chain including SEQ ID NO: 141; and (b) an amino acid sequence of a light chain including SEQ ID NO: 23; wherein the fusion protein comprises two heavy chains and two light chains; wherein a disulfide bond is formed between the first light chain and the first heavy chain, a disulfide bond is formed between the second light chain and the second heavy chain, and a disulfide bond is formed between the first heavy chain and the second heavy chain. Claim 14 In paragraph 13, the fusion protein has a binding affinity for human EGFR protein of 2.92 pM to 26.3 pM, or 7 pM to 9 pM, or 8.77 pM K D Having a value of 23 pM to 288.3 pM, or 64 pM to 144 pM, or 96.1 pM K for binding affinity to human TGF-β1 protein. D A fusion protein having a value. Claim 15 A conjugate comprising: (a) the cleaved TGFβR2 extracellular domain molecule described in claim 1, the fusion protein described in claim 2, or the antibody described in claim 9 or its antigen-binding fragment; and (b) additional therapeutic agent; Claim 16 In paragraph 15, the above antibody or its antigen-binding fragment and additional therapeutic agent are connected via a linker, forming a conjugate. Claim 17 A nucleic acid encoding the truncated TGFβR2 extracellular domain molecule described in claim 1, the fusion protein described in claim 2, or the antibody or antigen-binding fragment thereof described in claim 9, wherein the nucleic acid is mRNA or DNA. Claim 18 In claim 17, the nucleic acid comprises any one of sequence number: 32, 33, 36 and 37, or sequence number: 73, or sequence number:
153. Claim 19 An expression vector comprising the nucleic acid described in paragraph 17. Claim 20 An isolated host cell comprising the nucleic acid described in paragraph 17 or an expression vector containing said nucleic acid. Claim 21 A method for producing a truncated TGFβR2 extracellular domain molecule described in claim 1; a fusion protein described in claim 2; or an antibody or an antigen-binding fragment thereof described in claim 9; wherein the method comprises the steps of culturing a host cell under conditions suitable for the expression of said protein molecule and recovering an expressed product from said culture medium, wherein said host cell comprises a nucleic acid encoding the truncated TGFβR2 extracellular domain molecule described in claim 1; the fusion protein described in claim 2; or the antibody or an antigen-binding fragment thereof described in claim 9; or an expression vector comprising said nucleic acid. Claim 22 (a) a truncated TGFβR2 extracellular domain molecule as described in claim 1; a fusion protein comprising said truncated TGFβR2 extracellular domain molecule; an antibody or its antigen-binding fragment as described in claim 9; a conjugate comprising said truncated TGFβR2 extracellular domain molecule, said fusion protein, or said antibody or its antigen-binding fragment, and an additional therapeutic agent; a nucleic acid encoding said truncated TGFβR2 extracellular domain molecule, said fusion protein, or said antibody or its antigen-binding fragment; or an expression vector comprising said nucleic acid; and (b) a pharmaceutically acceptable carrier, comprising a pharmaceutically acceptable carrier. Claim 23 In paragraph 22, the above pharmaceutical composition comprises (c) one or more additional therapeutic agents. Claim 24 (a) a truncated TGFβR2 extracellular domain molecule as described in claim 1; a fusion protein comprising said truncated TGFβR2 extracellular domain molecule; an antibody or its antigen-binding fragment as described in claim 9; a conjugate comprising said truncated TGFβR2 extracellular domain molecule, said fusion protein, or said antibody or its antigen-binding fragment, and an additional therapeutic agent; a nucleic acid encoding said truncated TGFβR2 extracellular domain molecule, said fusion protein, or said antibody or its antigen-binding fragment; or an expression vector comprising said nucleic acid; and (b) one or more additional therapeutic agents, a pharmaceutical combination for the prevention and treatment of cancer or the treatment of gastric cancer. Claim 25 A kit for the prevention and treatment of cancer, or the treatment of gastric cancer, comprising: a truncated TGFβR2 extracellular domain molecule as described in claim 1; a fusion protein comprising said truncated TGFβR2 extracellular domain molecule; an antibody or its antigen-binding fragment as described in claim 9; a conjugate comprising said truncated TGFβR2 extracellular domain molecule, said fusion protein, or said antibody or its antigen-binding fragment, and an additional therapeutic agent; a nucleic acid encoding said truncated TGFβR2 extracellular domain molecule, said fusion protein, or said antibody or its antigen-binding fragment; or an expression vector comprising said nucleic acid. Claim 26 In paragraph 25, the above kit further comprises a device for administering a drug. Claim 27 A pharmaceutical composition for preventing or treating a neoplastic disease, comprising: a truncated TGFβR2 extracellular domain molecule as described in claim 1; a fusion protein as described in any one of claims 2 to 8, 13, and 14; an antibody or its antigen-binding fragment as described in any one of claims 9 to 11; a conjugate comprising the truncated TGFβR2 extracellular domain molecule, the fusion protein, or the antibody or its antigen-binding fragment, and an additional therapeutic agent; a nucleic acid encoding the truncated TGFβR2 extracellular domain molecule, the fusion protein, or the antibody or its antigen-binding fragment; or an expression vector comprising said nucleic acid.
Citation Information
Patent Citations
TGF-beta receptor type ii variants and uses thereof
WO2015027082A1
Fusion protein containing TGF-β receptor and pharmaceutical use thereof
KR1020200004801A
